<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79742</article-id><article-id pub-id-type="doi">10.7554/eLife.79742</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Associations of genetic and infectious risk factors with coronary heart disease</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-277670"><name><surname>Hodel</surname><given-names>Flavia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7331-7357</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280996"><name><surname>Xu</surname><given-names>Zhi Ming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280997"><name><surname>Thorball</surname><given-names>Christian Wandall</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280998"><name><surname>de La Harpe</surname><given-names>Roxane</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280999"><name><surname>Letang-Mathieu</surname><given-names>Prunelle</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281000"><name><surname>Brenner</surname><given-names>Nicole</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7690-4925</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281001"><name><surname>Butt</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281002"><name><surname>Bender</surname><given-names>Noemi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2542-9949</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281003"><name><surname>Waterboer</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281004"><name><surname>Marques-Vidal</surname><given-names>Pedro Manuel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4548-8500</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281005"><name><surname>Vollenweider</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281006"><name><surname>Vaucher</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-4798"><name><surname>Fellay</surname><given-names>Jacques</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8240-939X</contrib-id><email>jacques.fellay@epfl.ch</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02s376052</institution-id><institution>Global Health Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne</institution></institution-wrap><addr-line><named-content content-type="city">Lausanne</named-content></addr-line><country>Switzerland</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002n09z45</institution-id><institution>Swiss Institute of Bioinformatics</institution></institution-wrap><addr-line><named-content content-type="city">Lausanne</named-content></addr-line><country>Switzerland</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/019whta54</institution-id><institution>Precision Medicine Unit, Lausanne University Hospital and University of Lausanne</institution></institution-wrap><addr-line><named-content content-type="city">Lausanne</named-content></addr-line><country>Switzerland</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/019whta54</institution-id><institution>Department of Medicine, Internal medicine, Lausanne University Hospital and University of Lausanne</institution></institution-wrap><addr-line><named-content content-type="city">Lausanne</named-content></addr-line><country>Switzerland</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cdgtt98</institution-id><institution>Division of Infections and Cancer Epidemiology, German Cancer Research Center</institution></institution-wrap><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nsengimana</surname><given-names>Jérémie</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kj2bm70</institution-id><institution>Newcastle University</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>James</surname><given-names>David E</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0384j8v12</institution-id><institution>University of Sydney</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>14</day><month>02</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e79742</elocation-id><history><date date-type="received" iso-8601-date="2022-04-25"><day>25</day><month>04</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-22"><day>22</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-04-13"><day>13</day><month>04</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.04.13.22273812"/></event></pub-history><permissions><copyright-statement>© 2023, Hodel et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Hodel et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79742-v1.pdf"/><abstract><p>Coronary heart disease (CHD) is one of the most pressing health problems of our time and a major cause of preventable death. CHD results from complex interactions between genetic and environmental factors. Using multiplex serological testing for persistent or frequently recurring infections and genome-wide analysis in a prospective population study, we delineate the respective and combined influences of genetic variation, infections, and low-grade inflammation on the risk of incident CHD. Study participants are enrolled in the CoLaus|PsyCoLaus study, a longitudinal, population-based cohort with baseline assessments from 2003 through 2008 and follow-up visits every 5 years. We analyzed a subgroup of 3459 individuals with available genome-wide genotyping data and immunoglobulin G levels for 22 persistent or frequently recurring pathogens. All reported CHD events were evaluated by a panel of specialists. We identified independent associations with incident CHD using univariable and multivariable stepwise Cox proportional hazards regression analyses. Of the 3459 study participants, 210 (6.07%) had at least one CHD event during the 12 years of follow-up. Multivariable stepwise Cox regression analysis, adjusted for known cardiovascular risk factors, socioeconomic status, and statin intake, revealed that high polygenic risk (hazard ratio [HR] 1.31, 95% CI 1.10–1.56, p=2.64 × 10<sup>−3</sup>) and infection with <italic>Fusobacterium nucleatum</italic> (HR 1.63, 95% CI 1.08–2.45, p=1.99 × 10<sup>−2</sup>) were independently associated with incident CHD. In a prospective, population-based cohort, high polygenic risk and infection with <italic>F. nucleatum</italic> have a small, yet independent impact on CHD risk.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>coronary heart disease</kwd><kwd>persistent infections</kwd><kwd>inflammation</kwd><kwd>human genomics</kwd><kwd>Cox regression</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>31003A_175603</award-id><principal-award-recipient><name><surname>Fellay</surname><given-names>Jacques</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In a prospective, population-based cohort, high polygenic risk and infection with <italic>Fusobacterium nucleatum</italic> have a small, yet independent impact on coronary heart disease risk.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Worldwide, cardiovascular diseases (CVDs) are the leading cause of mortality (<xref ref-type="bibr" rid="bib51">Roth et al., 2018</xref>). An estimated 17.9 million people die from CVD each year, accounting for 32% of all deaths. CVD is a broad term for medical conditions involving the heart and blood vessels, such as coronary heart disease (CHD), congenital heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, deep vein thrombosis, and pulmonary embolism (<xref ref-type="bibr" rid="bib65">World Health Organization, 2009</xref>).</p><p>CHD is the most common type of heart disease (<xref ref-type="bibr" rid="bib51">Roth et al., 2018</xref>). It is caused by atherosclerosis, a build-up of plaque inside the walls of the arteries that supply blood to the heart. CHD progresses over a long period of time and eventually evolves into symptoms such as chest pain (angina), tightness in the chest, breathing difficulties, and pain in the arms or shoulders (<xref ref-type="bibr" rid="bib6">Ambrose and Singh, 2015</xref>). A complete blockage can cause a heart attack.</p><p>A combination of demographic, environmental, and genetic factors contribute to the development of CHD (<xref ref-type="bibr" rid="bib37">Khot et al., 2003</xref>; <xref ref-type="bibr" rid="bib46">Mendis et al., 2011</xref>). The main risk factors associated with the development of CHD – smoking, diabetes, hyperlipidemia, and hypertension – have been established by extensive epidemiological research (<xref ref-type="bibr" rid="bib43">MacMahon et al., 1990</xref>; <xref ref-type="bibr" rid="bib56">Stamler et al., 1993</xref>; <xref ref-type="bibr" rid="bib58">Verschuren et al., 1995</xref>; <xref ref-type="bibr" rid="bib64">Weintraub, 1990</xref>). Age is also an important risk factor for CHD (<xref ref-type="bibr" rid="bib16">Castelli, 1984</xref>). Finally, the incidence of CHD is greater in males than in females (<xref ref-type="bibr" rid="bib16">Castelli, 1984</xref>). Very recently, a new algorithm, named Systematic COronary Risk Evaluation 2 (SCORE2), was developed to predict the 10-year risk of first-onset CVD in European populations (<xref ref-type="bibr" rid="bib55">SCORE2 working group and ESC Cardiovascular risk collaboration, 2021</xref>; <xref ref-type="bibr" rid="bib54">SCORE2-OP working group and ESC Cardiovascular risk collaboration, 2021</xref>). This score has replaced the existing HeartScore scoring system, and incorporates most of the risk factors mentioned above (<xref ref-type="bibr" rid="bib18">Conroy et al., 2003</xref>).</p><p>CHD also has an important genetic component. In 1938, the first familial risk model for CHD was described and later confirmed by clinical observations and large studies of twins and of longitudinal cohorts (<xref ref-type="bibr" rid="bib48">Müller, 1938</xref>; <xref ref-type="bibr" rid="bib44">Marenberg et al., 1994</xref>; <xref ref-type="bibr" rid="bib53">Samani et al., 2007</xref>; <xref ref-type="bibr" rid="bib1">Abraham et al., 2016</xref>). Based on whole-genome approaches, the heritability of CHD has been estimated at 40–60%, even after controlling for known risk factors (<xref ref-type="bibr" rid="bib59">Vinkhuyzen et al., 2013</xref>).</p><p>Multiple clinical studies have identified inflammatory risk factors that are predictive of future cardiovascular events (<xref ref-type="bibr" rid="bib5">Alfaddagh et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Libby, 2006</xref>; <xref ref-type="bibr" rid="bib33">Hansson, 2005</xref>). Endothelial dysfunction and subintimal cholesterol have been shown to trigger an inflammatory cascade, involving activated macrophages and leading to atherosclerotic lesions. At the molecular level, inflammasome formation in macrophages plays, through their production of interleukin (IL)-1β, an essential role in the propagation of inflammation. These cytokines are released, trigger various inflammatory cells, and produce IL-6 that in turn, stimulate C-reactive protein (CRP) production by the liver, which further enhances the inflammatory cascade within the vascular wall. Today, CRP is an established biomarker of systemic inflammation and a possible predictor of future cardiovascular events (<xref ref-type="bibr" rid="bib41">Libby, 2006</xref>).</p><p>The recognition of atherosclerosis as an inflammatory disease has renewed interest in examining the role of pathogens in CHD and other CVDs. Nearly 150 years ago, acute infection with <italic>Bacillus typhosus</italic> was found to cause sclerosing changes in the arterial wall (<xref ref-type="bibr" rid="bib28">Gilbert and Lion, 1889</xref>). A century later, the interest for a potential role of infection in atherosclerosis was renewed, with the discovery that CHD-positive individuals show an increased likelihood of having elevated levels of antibodies to <italic>Chlamydia pneumoniae</italic> (<italic>C. pneumoniae</italic>) (<xref ref-type="bibr" rid="bib52">Saikku et al., 1988</xref>). This was followed by the discovery of the association with CHD of several other infectious agents, including bacteria and viruses, such as <italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>), hepatitis C virus (HCV), and human herpes viruses (<xref ref-type="bibr" rid="bib3">Adinolfi et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Filardo et al., 2015</xref>; <xref ref-type="bibr" rid="bib61">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib67">Zhang et al., 2008</xref>). The exact mechanisms linking infection to low-grade inflammation and atherosclerosis are still being studied, though some potential pathways have been proposed. One proposed mechanism involves the production of pro-inflammatory molecules in response to an infection (<xref ref-type="bibr" rid="bib15">Campbell and Rosenfeld, 2015</xref>). These molecules, such as cytokines, can increase the activity of cells involved in atherosclerosis, such as macrophages and smooth muscle cells, leading to the formation of plaques and other changes in the walls of arteries (<xref ref-type="bibr" rid="bib15">Campbell and Rosenfeld, 2015</xref>). Another mechanism is related to the inflammation at the site of vessel wall. Specifically, it is characterized by the presence of the infectious agents within the atherosclerotic plaques. The infectious consequences on the atherosclerotic plaque can be accelerated progression or a final complication like thrombosis and plaque rupture (<xref ref-type="bibr" rid="bib49">Pedicino et al., 2013</xref>).</p><p>Although enormous progress has been made in the understanding of CHD pathogenesis, the overall picture of the combined contribution of infectious, inflammatory, and genetic factors to the risk of developing CHD in the general population remains incomplete. We here use data from the CoLaus|PsyCoLaus study, a well-characterized, longitudinal, population-based study from Switzerland, to obtain a more comprehensive view of the evidence for the respective contributions of these factors to CHD.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Demographic and serological characteristics</title><p>A total of 3459 CoLaus|PsyCoLaus participants with available phenotypic, serological, and genotypic data were included. Their characteristics are presented in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Baseline characteristics of 3459 CoLaus|PsyCoLaus participants by coronary heart disease (CHD) cases and controls.</title><p>p-Values are based on the t-test for continuous variables and Fisher’s exact test for categorical variables comparing the CHD cases and controls group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">OverallN = 3249 (100%)</th><th align="left" valign="bottom">ControlsN = 3249 (93.93%)</th><th align="left" valign="bottom">CHD casesN = 210 (6.07%)</th><th align="left" valign="bottom">p</th></tr><tr><th align="left" valign="bottom">Baseline characteristics</th><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/></tr></thead><tbody><tr><td align="left" valign="bottom">Age (mean [SD])</td><td align="left" valign="bottom">52.83 [10.48]</td><td align="left" valign="bottom">52.34 [10.36]</td><td align="left" valign="bottom">60.34 [9.53]</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom">BMI (mean [SD])</td><td align="left" valign="bottom">25.51 [4.31]</td><td align="left" valign="bottom">25.41 [4.27]</td><td align="left" valign="bottom">27.11 [4.62]</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom">Systolic blood pressure (mean [SD])</td><td align="left" valign="bottom">129.04 [18.40]</td><td align="left" valign="bottom">128.32 [18.01]</td><td align="left" valign="bottom">140.18 [20.60]</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom">HDL cholesterol (mean [SD])</td><td align="left" valign="bottom">1.66 [0.43]</td><td align="left" valign="bottom">1.67 [0.43]</td><td align="left" valign="bottom">1.49 [0.41]</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom">LDL cholesterol (mean [SD])</td><td align="left" valign="bottom">3.34 [0.92]</td><td align="left" valign="bottom">3.33 [0.92]</td><td align="left" valign="bottom">3.48 [0.91]</td><td align="left" valign="bottom"><bold>0.018</bold></td></tr><tr><td align="left" valign="bottom">Total cholesterol (mean [SD])</td><td align="left" valign="bottom">5.60 [1.03]</td><td align="left" valign="bottom">5.59 [1.02]</td><td align="left" valign="bottom">5.73 [1.04]</td><td align="left" valign="bottom">0.051</td></tr><tr><td align="left" valign="bottom">Sex = male (%)</td><td align="left" valign="bottom">1592 (46.0)</td><td align="left" valign="bottom">1448 (44.6)</td><td align="left" valign="bottom">144 (68.6)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom">Statin = yes (%)</td><td align="left" valign="bottom">296 (8.6)</td><td align="left" valign="bottom">242 (7.4)</td><td align="left" valign="bottom">54 (25.7)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom">Average gross monthly income (in CHF):</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>0.029</bold></td></tr><tr><td align="left" valign="bottom">&lt;2999 (%)</td><td align="left" valign="bottom">178 (5.1)</td><td align="left" valign="bottom">161 (5.0)</td><td align="left" valign="bottom">17 (8.1)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">3000–4999 (%)</td><td align="left" valign="bottom">452 (13.1)</td><td align="left" valign="bottom">425 (13.1)</td><td align="left" valign="bottom">27 (12.9)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">5000–6999 (%)</td><td align="left" valign="bottom">552 (16.0)</td><td align="left" valign="bottom">517 (15.9)</td><td align="left" valign="bottom">35 (16.7)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">7000–9499 (%)</td><td align="left" valign="bottom">504 (14.6)</td><td align="left" valign="bottom">468 (14.4)</td><td align="left" valign="bottom">36 (17.1)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">9500–13,000 (%)</td><td align="left" valign="bottom">338 (9.8)</td><td align="left" valign="bottom">323 (9.9)</td><td align="left" valign="bottom">15 (7.1)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">&gt;13,000 (%)</td><td align="left" valign="bottom">344 (9.9)</td><td align="left" valign="bottom">335 (10.3)</td><td align="left" valign="bottom">9 (4.3)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Refused or missing (%)</td><td align="left" valign="bottom">1091 (31.5)</td><td align="left" valign="bottom">1020 (31.4)</td><td align="left" valign="bottom">71 (33.8)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Smoking = yes (%)</td><td align="left" valign="bottom">883 (25.5)</td><td align="left" valign="bottom">820 (25.2)</td><td align="left" valign="bottom">63 (30.0)</td><td align="left" valign="bottom">0.146</td></tr><tr><td align="left" valign="bottom"><bold>Genetics</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">CHD-PRS (mean [SD])</td><td align="left" valign="bottom">0.00 [1.00]</td><td align="left" valign="bottom">−0.02 [0.99]</td><td align="left" valign="bottom">0.26 [1.01<bold>]</bold></td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom"><bold>Biomarkers of inflammation</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">hs-CRP (mean [SD])</td><td align="left" valign="bottom">0.09 [0.46]</td><td align="left" valign="bottom">0.08 [0.46]</td><td align="left" valign="bottom">0.22 [0.44]</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom">TNF-α (mean [SD]) – 63 NAs</td><td align="left" valign="bottom">0.46 [0.38]</td><td align="left" valign="bottom">0.46 [0.38]</td><td align="left" valign="bottom">0.53 [0.35]</td><td align="left" valign="bottom"><bold>0.013</bold></td></tr><tr><td align="left" valign="bottom">IL-1β (mean [SD]) – 1’319 NAs</td><td align="left" valign="bottom">0.17 [0.64]</td><td align="left" valign="bottom">0.17 [0.64]</td><td align="left" valign="bottom">0.14 [0.67]</td><td align="left" valign="bottom">0.637</td></tr><tr><td align="left" valign="bottom">IL-6 (mean [SD]) – 294 NAs</td><td align="left" valign="bottom">0.24 [0.58]</td><td align="left" valign="bottom">0.24 [0.58]</td><td align="left" valign="bottom">0.28 [0.55]</td><td align="left" valign="bottom">0.398</td></tr><tr><td align="left" valign="bottom"><bold>Persistent pathogens</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Human polyomaviruses:</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">BKPyV = seropositive (%)</td><td align="left" valign="bottom">2912 (84.2)</td><td align="left" valign="bottom">2735 (84.2)</td><td align="left" valign="bottom">177 (84.3)</td><td align="left" valign="bottom">1.000</td></tr><tr><td align="left" valign="bottom">JCPyV = seropositive (%)</td><td align="left" valign="bottom">1812 (52.4)</td><td align="left" valign="bottom">1696 (52.2)</td><td align="left" valign="bottom">116 (55.2)</td><td align="left" valign="bottom">0.434</td></tr><tr><td align="left" valign="bottom">HPyV6 = seropositive (%)</td><td align="left" valign="bottom">2948 (85.2)</td><td align="left" valign="bottom">2759 (84.9)</td><td align="left" valign="bottom">189 (90.0)</td><td align="left" valign="bottom">0.056</td></tr><tr><td align="left" valign="bottom">WUPyV = seropositive (%)</td><td align="left" valign="bottom">3309 (95.7)</td><td align="left" valign="bottom">3105 (95.6)</td><td align="left" valign="bottom">204 (97.1)</td><td align="left" valign="bottom">0.362</td></tr><tr><td align="left" valign="bottom">Human herpes viruses:</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">HSV-1 = seropositive (%)</td><td align="left" valign="bottom">2547 (73.6)</td><td align="left" valign="bottom">2373 (73.0)</td><td align="left" valign="bottom">174 (82.9)</td><td align="left" valign="bottom"><bold>0.002</bold></td></tr><tr><td align="left" valign="bottom">HSV-2 = seropositive (%)</td><td align="left" valign="bottom">601 (17.4)</td><td align="left" valign="bottom">564 (17.4)</td><td align="left" valign="bottom">37 (17.6)</td><td align="left" valign="bottom">0.998</td></tr><tr><td align="left" valign="bottom">CMV = seropositive (%)</td><td align="left" valign="bottom">1868 (54.0)</td><td align="left" valign="bottom">1756 (54.0)</td><td align="left" valign="bottom">112 (53.3)</td><td align="left" valign="bottom">0.897</td></tr><tr><td align="left" valign="bottom">EBV = seropositive (%)</td><td align="left" valign="bottom">3350 (96.8)</td><td align="left" valign="bottom">3147 (96.9)</td><td align="left" valign="bottom">203 (96.7)</td><td align="left" valign="bottom">1.000</td></tr><tr><td align="left" valign="bottom">HHV-6A = seropositive (%)</td><td align="left" valign="bottom">865 (25.0)</td><td align="left" valign="bottom">800 (24.6)</td><td align="left" valign="bottom">65 (31.0)</td><td align="left" valign="bottom"><bold>0.049</bold></td></tr><tr><td align="left" valign="bottom">HHV-6B = seropositive (%)</td><td align="left" valign="bottom">1373 (39.7)</td><td align="left" valign="bottom">1295 (39.9)</td><td align="left" valign="bottom">78 (37.1)</td><td align="left" valign="bottom">0.480</td></tr><tr><td align="left" valign="bottom">HHV-7 = seropositive (%)</td><td align="left" valign="bottom">1846 (53.4)</td><td align="left" valign="bottom">1746 (53.7)</td><td align="left" valign="bottom">100 (47.6)</td><td align="left" valign="bottom">0.099</td></tr><tr><td align="left" valign="bottom">KSHV = seropositive (%)</td><td align="left" valign="bottom">141 (4.1)</td><td align="left" valign="bottom">133 (4.1)</td><td align="left" valign="bottom">8 (3.8)</td><td align="left" valign="bottom">0.983</td></tr><tr><td align="left" valign="bottom">VZV = seropositive (%)</td><td align="left" valign="bottom">3047 (88.1)</td><td align="left" valign="bottom">2853 (87.8)</td><td align="left" valign="bottom">194 (92.4)</td><td align="left" valign="bottom">0.061</td></tr><tr><td align="left" valign="bottom">Parvovirus:</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">PVB-19 = seropositive (%)</td><td align="left" valign="bottom">2420 (70.0)</td><td align="left" valign="bottom">2277 (70.1)</td><td align="left" valign="bottom">143 (68.1)</td><td align="left" valign="bottom">0.595</td></tr><tr><td align="left" valign="bottom">Bacteria:</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>C. trachomatis</italic> = seropositive (%)</td><td align="left" valign="bottom">1213 (35.1)</td><td align="left" valign="bottom">1120 (34.5)</td><td align="left" valign="bottom">93 (44.3)</td><td align="left" valign="bottom"><bold>0.005</bold></td></tr><tr><td align="left" valign="bottom"><italic>F. nucleatum</italic> = seropositive (%)</td><td align="left" valign="bottom">520 (15.0)</td><td align="left" valign="bottom">473 (14.6)</td><td align="left" valign="bottom">47 (22.4)</td><td align="left" valign="bottom"><bold>0.003</bold></td></tr><tr><td align="left" valign="bottom"><italic>H. pylori</italic> = seropositive (%)</td><td align="left" valign="bottom">685 (19.8)</td><td align="left" valign="bottom">645 (19.9)</td><td align="left" valign="bottom">40 (19.0)</td><td align="left" valign="bottom">0.846</td></tr><tr><td align="left" valign="bottom"><italic>S. gallolyticus</italic> = seropositive (%)</td><td align="left" valign="bottom">135 (3.9)</td><td align="left" valign="bottom">130 (4.0)</td><td align="left" valign="bottom">5 (2.4)</td><td align="left" valign="bottom">0.322</td></tr><tr><td align="left" valign="bottom">Parasite:</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>T. gondii</italic> = seropositive (%)</td><td align="left" valign="bottom">1445 (41.8)</td><td align="left" valign="bottom">1349 (41.5)</td><td align="left" valign="bottom">96 (45.7)</td><td align="left" valign="bottom">0.262</td></tr></tbody></table></table-wrap><p>During the follow-up of 4500 days (12.3 years), at least one CHD event occurred in 210 individuals (6.07%). The number of participants with one, two, and three coronary events was 140, 47, and 14, respectively. Nine individuals had between four and eight coronary events. Eligible study participants were on average 52.8 (standard deviation [SD] ± 10.5) years of age at baseline, 54% were women and 25.5% were smokers. On average, their body mass index (BMI) was 25.5 (±4.3) kg/m<sup>2</sup>, their systolic blood pressure was 129 (±18) mmHg, and their HDL cholesterol level was 1.66 (±0.43) mmol/L. The percentages of participants by average gross monthly income are 7.5 (&lt;CHF 2999), 19.1 (CHF 3000–4999), 23.3 (CHF 5000–6999), 21.3 (CHF 7000–9499), 14.3 (CHF 9500–13,000), and 14.5% (CHF &gt; 13,000).</p><p>For the measured biomarkers of inflammation, the log10-transformed mean (SD) values for high-sensitive CRP (hs-CRP), IL-1β, IL-6, and tumor necrosis factor α (TNF-α) were 0.09 (±0.46), 0.17 (±0.64), 0.24 (±0.58), and 0.46 (±0.38), respectively.</p><p>We also investigated participants’ serostatus for the following 22 human pathogens: 15 viruses (human polyomaviruses BK [BKV], JC [JCV], 6 [HPyV6], and WU [WUPyV], herpes simplex virus [HSV]-1, HSV-2, varicella zoster virus (VZV), Epstein–Barr virus [EBV], cytomegalovirus [CMV], human herpes virus 6A [HHV-6A], HHV-6B, HHV-7, Kaposi’s sarcoma-associated herpes virus [KSHV], parvovirus B19 [PVB-19], and rubella virus); six bacteria (<italic>Chlamydia trachomatis</italic> [<italic>C. trachomatis</italic>], <italic>Clostridium tetani</italic> [<italic>C. tetani</italic>], <italic>Cornybacterium diphteriae</italic> [<italic>C. diphteriae</italic>], <italic>F. nucleatum</italic>, <italic>H. pylori</italic>, and <italic>S. gallolyticus</italic>); and one parasite (<italic>T. gondii</italic>) (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). The overall seropositivity ranged from 3.99% (<italic>S. gallolyticus</italic>) to 96.80% (EBV). The overall serostatus split between CHD-positive (with at least one CHD event during follow-up) and CHD-negative individuals are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Rubella, <italic>C. tetani</italic> and <italic>C. diphteriae</italic> were excluded from further analyses as the antibodies detected against these pathogens were most likely induced by vaccination.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Prevalence of tested pathogens in CoLaus|PsyCoLaus study in participants with and without coronary heart disease (CHD).</title><p>Overall serostatus for the 22 pathogens are shown in the CHD-positive group (individuals with at least one CHD event during follow-up) or CHD-negative group. The y-axis indicates the relative percentage within each group. Pathogens are ranked in ascending order of overall seropositivity (all individuals combined).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Data underlying <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79742-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79742-fig1-v1.tif"/></fig></sec><sec id="s2-2"><title>Univariable predictors of CHD incidence</title><p>To validate the utility of SCORE2 in our cohort, we tested its association with CHD. SCORE2 was significantly and positively associated with CHD (HR 1.72, 95% CI 1.61–1.85, p = 2.87×10<sup>−61</sup>) (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>). We also observed a significant inverse association between average gross monthly income and CHD risk (HR 0.85, 95% CI 0.76–0.96, p = 7.27×10<sup>−3</sup>).</p><p>To investigate the relationship between CHD and humoral response to infectious agents, we tested the association of serostatus for each of the included 19 persistent or frequently occurring pathogens with CHD. We found significant positive associations for six of them, including three herpes viruses, namely HSV-1 (HR 1.88, 95% CI 1.30–2.68, p = 6.52×10<sup>−4</sup>), HHV-6A (HR 1.39, 95% CI 1.03–1.86, p = 2.89×10<sup>−2</sup>), and VZV (HR 1.70, 95% CI 1.02–2.82, p = 4.25×10<sup>−2</sup>), one polyomavirus, HPyV6 (HR 1.66, 95% CI 1.06–2.61, p = 2.74×10<sup>−2</sup>), and two bacteria, <italic>F. nucleatum</italic> (HR 1.66, 95% CI 1.20–2.29, p = 2.32×10<sup>−3</sup>), and <italic>C. trachomatis</italic> (HR 1.45, 95% CI 1.11–1.91, p = 7.22×10<sup>−3</sup>) (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>).</p><p>To evaluate the impact of the biomarkers of inflammation on CHD risk, we tested the association of log10-transformed levels of hs-CRP, IL-1β, IL-6, and TNF-α with CHD. We observed a positive relationship between individuals’ hs-CRP (HR 1.91, 95% CI 1.42–2.55, p = 1.51×10<sup>−5</sup>) and TNF-α (HR 1.43, 95% CI 1.05–1.96, p = 2.46×10<sup>−2</sup>) levels, and increased risk of CHD event (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>).</p><p>Finally, we calculated a CHD polygenic risk score (CHD-PRS) for each subject to investigate the effect of common human genetic variations on CHD. As expected, we observed a significant association between the PRS and CHD (HR 1.32, 95% CI 1.16–1.51, p = 4.29×10<sup>−5</sup>), confirming that genetic predisposition to CHD can be captured through CHD-PRS. The top three genetic principal components (PC1, PC2, and PC3) were not significantly associated with CHD (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>).</p></sec><sec id="s2-3"><title>Co-linearity and proportional hazard assumption testing</title><p>We calculated pairwise correlations between all variables that were found to be significant in univariable analyses. <xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1</xref> and <xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2</xref> illustrate that no strong correlations exist between significant variables. The strongest correlation was observed between SCORE2 and hs-CRP, and between seropositivity to <italic>C. trachomatis</italic> and gross monthly household income, with Pearson’s and Cramer’s V coefficients of 0.22 and 0.15, respectively. The proportionality assumption was tested for all significant variables using the Schoenfeld residuals. The residual tests indicated that all variables satisfied the proportional hazards assumption, revealing that the effect of all covariates are constant in time (<xref ref-type="fig" rid="app2fig3">Appendix 2—figure 3</xref>). Finally, we also assessed potential co-linearity issues among predictors that could affect model fitting. No variance inflation factor (VIF) value was indicative of co-linearity.</p></sec><sec id="s2-4"><title>Multivariable model</title><p>To identify the independent risk factors of CHD in our cohort, we performed backward stepwise selection on 2323 individuals with non-missing data using a multivariable Cox proportional hazards model, starting with all the significant factors from the univariable models. The final multivariable analysis confirmed that SCORE2 (HR 1.96 per SD increase, 95% CI 1.74–2.22, p = 2.42×10<sup>−27</sup>) is an independent prognostic factor of CHD (<xref ref-type="fig" rid="fig2">Figure 2</xref>). We also observed significant independent associations for statin intake (HR 2.24, 95% CI 1.50–3.35, p = 9.17×10<sup>−5</sup>) and for seropositivity to <italic>F. nucleatum</italic> infection (HR 1.63, 95% CI 1.08–2.45, p = 1.99×10<sup>−2</sup>). Comparing individuals who had a least one CHD event (CHD group) against those who had no event during the follow-up period (control group), 22.4% (47/210) of the individuals in the CHD group were seropositive to <italic>F. nucleatum</italic>, versus 14.6% (473/3249) in the control group (p = 0.003) (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Lastly, we also observed a significant association between CHD occurrence and elevated CHD-PRS with an HR of 1.31 (95% CI 1.10–1.56, p = 3.32×10<sup>−3</sup>) per SD increase.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Hazard ratio (HR) and 95% confidence intervals of coronary heart disease (CHD) occurrence according to associated factors.</title><p>HR &gt; 1 indicates an increased risk of CHD, whereas HR &lt; 1 indicates a protective effect. p-Values (<bold>p</bold>) for each factor based on the multivariable Cox regression are shown.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Data underlying <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79742-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79742-fig2-v1.tif"/></fig><p>To assess if the overall burden of infections contributed to increased risk of CHD, study participants were stratified according to their overall seropositivity index for measured pathogens, calculated by summing the number of pathogens for which they show seropositivity (range: 0–16). The numbers of individuals in each pathogen burden stratum are shown in <xref ref-type="fig" rid="app2fig4">Appendix 2—figure 4</xref>. In the univariable Cox model, pathogen burden significantly increased the risk of CHD occurrence (HR 1.11, 95% CI 1.03–1.18, p = 3.25×10<sup>−3</sup>) (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>). However, after adjustment with multivariable Cox proportional hazards regression, pathogen burden did not meet the level of significance for staying in the model.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>CHD is a complex disease that is influenced by demographic, environmental, and genetic factors (<xref ref-type="bibr" rid="bib37">Khot et al., 2003</xref>; <xref ref-type="bibr" rid="bib46">Mendis et al., 2011</xref>). Infections have also been suspected to increase the risk of CHD, directly or through the induction of chronic inflammation (<xref ref-type="bibr" rid="bib60">Vojdani, 2003</xref>). The present study investigated the independent and combined effects of these risk factors as possible prognostic indicators for the occurrence of CHD. We performed an event-free survival analysis of incident CHD using data from a longitudinal, population-based study, in which more than 6% of participants developed CHD over a 12-year study period.</p><p>We confirmed the utility of SCORE2 to predict CHD risk in our cohort (<xref ref-type="bibr" rid="bib55">SCORE2 working group and ESC Cardiovascular risk collaboration, 2021</xref>). Of note, chronic inflammation reflected in hs-CRP level did not appear as an independent predictor of CHD in our analyses, as the univariable association signal was suppressed after adjustment for SCORE2 levels.</p><p>We studied the effect of human genetic determinants on CHD occurrence using PRS, and we reproduced previously observed effects: participants with a higher CHD-PRS have a greater risk of CHD, even after adjustment for all known factors (<xref ref-type="bibr" rid="bib20">Ding et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Kullo et al., 2016</xref>). This result confirms the existence of genetic susceptibility loci for CHD, and that the individual genetic background modulates CHD risk independently from age, sex, or co-morbidities. Our work confirms the potential interest in using PRS to improve the prediction of coronary events.</p><p>We also evaluated the potential contribution of multiple persistent or frequently recurring pathogens to CHD after controlling for conventional CHD risk factors, socioeconomic status, and human genetic variability. We observed an association of CHD with detection of antibodies against <italic>F. nucleatum</italic>. This pathogen is very prevalent in humans (<xref ref-type="bibr" rid="bib2">Adams et al., 2004</xref>; <xref ref-type="bibr" rid="bib4">Afra et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Looker et al., 2015</xref>). <italic>F. nucleatum</italic> is an anaerobic bacterium that belongs to the normal flora of the oral cavity and plays an important role in the development and progression of oral diseases, such as gingivitis (gum inflammation) and periodontitis (infection of the gums). Under pathological conditions, the pathogen can spread by the hematogenous route to extra-oral systemic sites, including the gut and the female genital tract (<xref ref-type="bibr" rid="bib31">Han and Wang, 2013</xref>; <xref ref-type="bibr" rid="bib30">Han et al., 2004</xref>). Studies have also suggested the involvement of <italic>F. nucleatum</italic> in CVD. First, by its capacity to directly migrate into arterial plaques, thus exacerbating atherosclerosis, and more recently, through the association of periodontitis and CVD (<xref ref-type="bibr" rid="bib36">Kholy et al., 2015</xref>; <xref ref-type="bibr" rid="bib21">Elkaïm et al., 2008</xref>; <xref ref-type="bibr" rid="bib23">Figuero et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Ford et al., 2006</xref>; <xref ref-type="bibr" rid="bib32">Han, 2015</xref>; <xref ref-type="bibr" rid="bib66">Zardawi et al., 2020</xref>). Finally, it has been shown that periodontal pathogens are able to spread through the bloodstream from the buccal cavity to the arteries in patients with detectable coronary calcium, a very specific marker of atherosclerosis (<xref ref-type="bibr" rid="bib19">Corredor et al., 2022</xref>). In summary, the relationship between oral inflammations and CVD could be explained by the colonization of arterial walls and atherosclerosis plaques by dental bacteria, as well as by increased systemic inflammation due to oral infection. However, to date, no direct causality has been established. Besides, no genome-wide association study on <italic>F. nucleatum</italic> has been published, neither on humoral immune response (i.e., IgG levels) nor on susceptibility to infection/colonization (i.e., serostatus).</p><p>HSV-1, HHV-6A, VZV, HPyV6, and <italic>C. trachomatis</italic> serologies, as well as total burden of infection, were associated with CHD occurrence in univariable models. However, these factors were not significantly associated in the multivariable analysis, suggesting that at least some of them could be indirect markers of socioeconomic status.</p><p>Our data do not support the existence of the previously identified associations between CHD and <italic>H. pylori</italic>, or CMV. The conflicting reports of possible associations between these pathogens and CHD could be due to sample size but remain questionable. Further extensive, and high-quality studies are needed to thoroughly examine these associations and provide firm conclusions.</p><p>Our study has several limitations. As is the case for most longitudinal studies, the absence of data on individuals who dropped out before the end of the follow-up implies that some CHD events could have gone undetected. Also, the demographic information, as well as the clinical and laboratory measurements, were obtained at baseline, and we do not know whether participant information changed over time. Adjustment for risk factors measured at baseline does not account for clinical or demographic changes that could influence CHD outcomes. Similarly, we do not know how the antibody responses against the various antigens evolved over the 12 years of the study. In addition, no significance adjustment was performed when using multiple univariable tests to determine the effect of single factors on CHD risk, although this may increase the false positive rate. Moreover, we were unable to replicate previously published observations of associations of CHD with <italic>C. pneumoniae</italic> and HCV as serologies for these pathogens were not available. From a more practical point of view, the identified association with <italic>F. nucleatum</italic> needs to be replicated and validated in independent cohorts and different populations. Finally, the clinical utility of including genetic and infection biomarkers in CHD prediction algorithms will need to be demonstrated.</p><sec id="s3-1"><title>Conclusion</title><p>CHD is a multicomponent disease that is caused by demographic, environmental, and genetic factors. Inflammation, possibly caused by persistent or frequently recurring infections, can contribute to its development. We identified a statistically significant association between the incidence of CHD and <italic>F. nucleatum</italic> infection, after adjustment for all established risk factors. We also confirmed that the individual polygenic risk of CVD, calculated from genome-wide genotypes, represents an independent risk factor for incident CHD. Our results can help to better identify subjects at high risk for CHD and provide a rationale for future anti-infective prevention trials.</p></sec></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Study cohort</title><p>The CoLaus|PsyCoLaus study is a longitudinal population-based study initiated in Lausanne in 2003; it mainly investigates the biological, environmental, and genetic determinants of CVD (<ext-link ext-link-type="uri" xlink:href="https://www.colaus-psycolaus.ch/">https://www.colaus-psycolaus.ch/</ext-link>) (<xref ref-type="bibr" rid="bib25">Firmann et al., 2008</xref>). The study involves over 6500 participants of European ancestry, who were recruited at random from the general population and represent approximately 10% sample of Lausanne citizens. Of the participants, 47.5% are men, and age at enrolment ranged from 35 to 75 years (mean ± SD: 51 ± 10.9). The study participants provided detailed phenotypic information through questionnaires, interviews, clinical and biological data. Nuclear deoxyribonucleic acid (DNA) was also extracted from the blood for whole-genome genotyping data. Every 5 years, follow-up interviews on the participants’ lifestyle and health status are conducted. There are three completed follow-ups and a fourth follow-up began in January 2022. The institutional Ethics Committee of the University of Lausanne, which later became the Ethics Commission of the Canton Vaud (<ext-link ext-link-type="uri" xlink:href="https://www.cer-vd.ch/">https://www.cer-vd.ch/</ext-link>), approved the CoLaus|PsyCoLaus study (reference 16/03, decisions of January 13 and February 10, 2003), and all participants gave written consent.</p></sec><sec id="s4-2"><title>Cardiovascular phenotype</title><p>The medical records of the participants who reported a CHD event during their lifetime were collected and evaluated by an independent panel of specialists. Information on the cause of death was also collected prospectively during the study period. The full procedure was described previously (<xref ref-type="bibr" rid="bib8">Beuret et al., 2021</xref>). Only first events occurring after the baseline and up to day 4500 after the baseline were included in the analysis, as only during this period were all participants reliably followed.</p></sec><sec id="s4-3"><title>DNA genotyping data and PRS calculation for cardiovascular phenotypes</title><p>The BB2 GSK-customized Affymetrix Axiom Biobank array was used to genotype DNA samples from 5399 participants at approximately 800,000 single nucleotide polymorphisms (SNPs). After genotype imputation and quality control procedures, approximately 9 million SNPs were available for analysis (<xref ref-type="bibr" rid="bib34">Hodel et al., 2021</xref>). We then calculated, based on the risk effects of common SNPs, the CHD-PRS for each study participant. We used validated PRS from Inouye et al., available in the polygenic score catalog (<xref ref-type="bibr" rid="bib35">Inouye et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Lambert et al., 2021</xref>). These scores and summary statistics were used to construct the CHD-PRS in our target cohort data by using the clumping and thresholding method of the PRSice-2 v2.2.7 software (<xref ref-type="bibr" rid="bib17">Choi et al., 2020</xref>). A standardized method was used to obtain the PRS, by multiplying the risk allele dosage for each variant by the effect size and summing the scores across all selected variants. SNPs were clumped according to linkage disequilibrium (r2 &lt; 0.1) within a 250 kb window.</p></sec><sec id="s4-4"><title>CHD risk evaluation</title><p>The risk of CHD for each participant was also assessed using the very recent SCORE2 and SCORE2-Older Persons (SCORE2-OP, for individuals &gt;65 years of age) algorithms (<xref ref-type="bibr" rid="bib54">SCORE2-OP working group and ESC Cardiovascular risk collaboration, 2021</xref>; <xref ref-type="bibr" rid="bib55">SCORE2 working group and ESC Cardiovascular risk collaboration, 2021</xref>). These two algorithms will be referred to as SCORE2. SCORE2 was derived, calibrated, and validated to predict the 10-year risk of first-onset CVD using data from 13 million individuals from &gt;50 European prospective studies and national registries. To develop this algorithm, the authors used competing risk-adjusted and age- and sex-specific models including age, current smoking, systolic blood pressure, and total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol. The authors also defined four risk regions in Europe on the basis of country-specific CVD mortality. For CoLaus|PsyCoLaus participants, calculations were based on the low-risk region corresponding to Switzerland. The raw scores of participants were standardized to Z-scores with approximately zero mean and unit variance before data analysis.</p></sec><sec id="s4-5"><title>Measurement of inflammatory biomarkers</title><p>Venous blood samples (50 mL) of the participants, in a fasted state, were drawn. Before cytokine assessment, the serum blood samples were stored at −80°C, then they were sent to the laboratory on dry ice. The measurements of hs-CRP, IL-1β, IL-6, and TNF-α cytokine levels were described previously in detail (<xref ref-type="bibr" rid="bib45">Marques-Vidal et al., 2011</xref>). Briefly, hs-CRP levels were assessed by immunoassay and latex HS (IMMULITE 1000-High, Diagnostic Products Corporation, Los Angeles, CA, USA). Cytokine levels were measured using a multiplexed particle-based flow cytometric cytokine assay on the flow cytometer (FC500 MPL, BeckmanCoulter, Nyon, Switzerland), thus following the manufacturer’s instructions. The lower limits of detection for IL-1β, IL-6, and TNF-α were 0.2 pg/mL. Intra- and inter-assay coefficients of variation were, respectively, 15% and 16.7% for IL-1β, 16.9% and 16.1% for IL-6, and 12.5% and 13.5% for TNF-α. For quality control, repeat measurements were performed on 80 subjects randomly selected from the initial sample. Individuals with hs-CRP levels above 20 mg/L were assigned a value of 20 by the manufacturer therefore were removed from the hs-CRP analyses as indicative of acute inflammation.</p></sec><sec id="s4-6"><title>Serological analyses</title><p>To assess the humoral responses to a total of 38 antigens derived from 22 persistent infectious agents, serum samples were analyzed by the Infections and Cancer Epidemiology Division at the German Cancer Research Center (Deutsches Krebsforschungszentrum [DKFZ]) in Heidelberg (<xref ref-type="bibr" rid="bib62">Waterboer et al., 2005</xref>; <xref ref-type="bibr" rid="bib63">Waterboer et al., 2006</xref>). Studied pathogens included 15 viruses (BKV, JCV, HPyV6, WUPyV, HSV-1, HSV-2, VZV, EBV, CMV, HHV-6A, HHV-6B, HHV-7, KSHV, PVB-19, and rubella virus); six bacteria (<italic>C. diphteriae</italic>, <italic>C. tetani</italic>, <italic>C. trachomatis</italic>, <italic>F. nucleatum</italic>, <italic>H. pylori</italic>, and <italic>S. gallolyticus</italic>); and one parasite (<italic>T. gondii</italic>) (for details, see <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). The seroreactivity was measured at a serum dilution of 1:1000 by using multiplex serology based on glutathione S-transferase fusion capture immunosorbent assays combined with fluorescent bead technology. For each infectious agent tested, the antibody responses were measured for one to six antigens and then expressed as a binary result (IgG positive or negative), based on the predefined median fluorescence intensity thresholds. To define overall seropositivity against infectious agents when more than one antigen was used, we applied the pathogen-specific algorithms suggested by the manufacturer (see references in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>).</p></sec><sec id="s4-7"><title>Statistical analyses</title><p>Univariable and multivariable Cox proportional hazard models were used to explore the relationship between risk factors and CHD incidence in the CoLaus|PsyCoLaus study. Each variable was first screened in the univariable model. To identify potential confounding due to population structure, we also tested the top three genetic principal components (PC1, PC2, and PC3) for association with CHD. We then examined the proportional hazards assumption of the significant (p &lt; 0.05) covariates by using the scaled Schoenfeld residuals. The residuals were plotted over time for each covariate to test for time independence. Risk factors significantly associated with CHD in the univariable model were further evaluated using pairwise correlations. Finally, the identified risk factors were assessed using multivariable stepwise Cox regression analysis, adjusted for competing risk (i.e., SCORE2), socioeconomic status (i.e., gross monthly household income), and statin intake. Potential multicollinearity between statistically significant factors (p &lt; 0.05) were identified using VIFs. The existence of multicollinearity between co-variates was determined by a VIF value &gt; 2. We performed all statistical analyses using R (version 4.2.1).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Software, Formal analysis, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con4"><p>Resources</p></fn><fn fn-type="con" id="con5"><p>Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con10"><p>Resources, Data curation, Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con13"><p>Supervision, Funding acquisition, Writing – original draft, Project administration</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The institutional Ethics Committee of the University of Lausanne, which later became the Ethics Commission of the Canton Vaud (www.cer-vd.ch), approved the CoLaus|PsyCoLaus study (reference 16/03, decisions of 13th January and 10th February 2003), and all participants gave written consent.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-79742-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The data of CoLaus|PsyCoLaus study used in this article cannot be fully shared as they contain potentially sensitive personal information on participants. According to the Ethics Committee for Research of the Canton of Vaud, sharing these data would be a violation of the Swiss legislation with respect to privacy protection. However, coded individual-level data that do not allow researchers to identify participants are available upon request to researchers who meet the criteria for data sharing of the CoLaus|PsyCoLaus Datacenter (CHUV, Lausanne, Switzerland). Any researcher affiliated to a public or private research institution who complies with the CoLaus|PsyCoLaus standards can submit a research application to <ext-link ext-link-type="uri" xlink:href="https://www.colaus-psycolaus.ch/">research.colaus@chuv.ch</ext-link> or <ext-link ext-link-type="uri" xlink:href="https://www.colaus-psycolaus.ch/professionals/psycolaus/">research.psycolaus@chuv.ch</ext-link>. Proposals requiring baseline data only, will be evaluated by the baseline (local) Scientific Committee (SC) of the CoLaus and PsyCoLaus studies. Proposals requiring follow-up data will be evaluated by the follow-up (multicentric) SC of the CoLaus|PsyCoLaus cohort study. Detailed instructions for gaining access to the CoLaus|PsyCoLaus data used in this study are available at <ext-link ext-link-type="uri" xlink:href="https://www.colaus-psycolaus.ch/professionals/how-to-collaborate/">https://www.colaus-psycolaus.ch/professionals/how-to-collaborate/</ext-link>. The underlying code used to analyze the data in this manuscript is publicly available on GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/flaviahodel/cox-chd-analysis">https://github.com/flaviahodel/cox-chd-analysis</ext-link>, copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:2e7b9a7909a1467f1781b104a4e8ef32d0f3706e;origin=https://github.com/flaviahodel/cox-chd-analysis;visit=swh:1:snp:4649f6f4e378691c5933b7de0cdc4a9297758e1d;anchor=swh:1:rev:317cf14e0fbf09f214b792cc5ea5a399739e15a1">swh:1:rev:317cf14e0fbf09f214b792cc5ea5a399739e15a1</ext-link>). Source Data files have been provided for all Figures and Figure Supplements. &quot;Figure 1 - Source Data&quot;, &quot;Figure 2 - Source Data&quot;, &quot;Figure S1 - Source Data&quot;, &quot;Figure S2 - Source Data&quot;, &quot;Figure S3 - Source Data&quot;, and &quot;Figure S4 - Source Data&quot; contain the numerical data used to generate the figures.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the participants in the CoLaus|PsyCoLaus study for their time and contribution to this study. We also thank all the clinical, academic, and administrative collaborators who helped with participant recruitment, study coordination, data collection, and storage. This project was supported by the Swiss National Science Foundation (grant 31003A_175603 to JF). The CoLaus|PsyCoLaus study was and is supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 3200B0_105993, 3200B0_118308, 33CSCO_122661, 33CS30_139468, 33CS30_148401, and 33CS30_177535/1).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>G</given-names></name><name><surname>Havulinna</surname><given-names>AS</given-names></name><name><surname>Bhalala</surname><given-names>OG</given-names></name><name><surname>Byars</surname><given-names>SG</given-names></name><name><surname>De Livera</surname><given-names>AM</given-names></name><name><surname>Yetukuri</surname><given-names>L</given-names></name><name><surname>Tikkanen</surname><given-names>E</given-names></name><name><surname>Perola</surname><given-names>M</given-names></name><name><surname>Schunkert</surname><given-names>H</given-names></name><name><surname>Sijbrands</surname><given-names>EJ</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Ripatti</surname><given-names>S</given-names></name><name><surname>Inouye</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic prediction of coronary heart disease</article-title><source>European Heart Journal</source><volume>37</volume><fpage>3267</fpage><lpage>3278</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw450</pub-id><pub-id pub-id-type="pmid">27655226</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>EJ</given-names></name><name><surname>Charlett</surname><given-names>A</given-names></name><name><surname>Edmunds</surname><given-names>WJ</given-names></name><name><surname>Hughes</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title><italic>Chlamydia trachomatis</italic> in the United Kingdom: a systematic review and analysis of prevalence studies</article-title><source>Sexually Transmitted Infections</source><volume>80</volume><fpage>354</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1136/sti.2003.005454</pub-id><pub-id pub-id-type="pmid">15459402</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adinolfi</surname><given-names>LE</given-names></name><name><surname>Rinaldi</surname><given-names>L</given-names></name><name><surname>Nevola</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Chronic hepatitis C, atherosclerosis and cardiovascular disease: what impact of direct-acting antiviral treatments?</article-title><source>World Journal of Gastroenterology</source><volume>24</volume><fpage>4617</fpage><lpage>4621</lpage><pub-id pub-id-type="doi">10.3748/wjg.v24.i41.4617</pub-id><pub-id pub-id-type="pmid">30416309</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afra</surname><given-names>K</given-names></name><name><surname>Laupland</surname><given-names>K</given-names></name><name><surname>Leal</surname><given-names>J</given-names></name><name><surname>Lloyd</surname><given-names>T</given-names></name><name><surname>Gregson</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Incidence, risk factors, and outcomes of fusobacterium species bacteremia</article-title><source>BMC Infectious Diseases</source><volume>13</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1186/1471-2334-13-264</pub-id><pub-id pub-id-type="pmid">23734900</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfaddagh</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>SS</given-names></name><name><surname>Leucker</surname><given-names>TM</given-names></name><name><surname>Michos</surname><given-names>ED</given-names></name><name><surname>Blaha</surname><given-names>MJ</given-names></name><name><surname>Lowenstein</surname><given-names>CJ</given-names></name><name><surname>Jones</surname><given-names>SR</given-names></name><name><surname>Toth</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inflammation and cardiovascular disease: from mechanisms to therapeutics</article-title><source>American Journal of Preventive Cardiology</source><volume>4</volume><elocation-id>100130</elocation-id><pub-id pub-id-type="doi">10.1016/j.ajpc.2020.100130</pub-id><pub-id pub-id-type="pmid">34327481</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrose</surname><given-names>JA</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pathophysiology of coronary artery disease leading to acute coronary syndromes</article-title><source>F1000prime Reports</source><volume>7</volume><elocation-id>08</elocation-id><pub-id pub-id-type="doi">10.12703/P7-08</pub-id><pub-id pub-id-type="pmid">25705391</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassig</surname><given-names>BA</given-names></name><name><surname>Willhauck-Fleckenstein</surname><given-names>M</given-names></name><name><surname>Shu</surname><given-names>XO</given-names></name><name><surname>Koh</surname><given-names>WP</given-names></name><name><surname>Gao</surname><given-names>YT</given-names></name><name><surname>Purdue</surname><given-names>MP</given-names></name><name><surname>Xiang</surname><given-names>YB</given-names></name><name><surname>Adams-Haduch</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Brenner</surname><given-names>N</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Ji</surname><given-names>BT</given-names></name><name><surname>Hosgood</surname><given-names>HD</given-names></name><name><surname>Rabkin</surname><given-names>CS</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Wong</surname><given-names>JYY</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Seow</surname><given-names>WJ</given-names></name><name><surname>Chow</surname><given-names>WH</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>JM</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Serologic markers of viral infection and risk of non-hodgkin lymphoma: a pooled study of three prospective cohorts in china and singapore</article-title><source>International Journal of Cancer</source><volume>143</volume><fpage>570</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1002/ijc.31385</pub-id><pub-id pub-id-type="pmid">29574937</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beuret</surname><given-names>H</given-names></name><name><surname>Hausler</surname><given-names>N</given-names></name><name><surname>Nanchen</surname><given-names>D</given-names></name><name><surname>Méan</surname><given-names>M</given-names></name><name><surname>Marques-Vidal</surname><given-names>P</given-names></name><name><surname>Vaucher</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comparison of swiss and european risk algorithms for cardiovascular prevention in switzerland</article-title><source>European Journal of Preventive Cardiology</source><volume>28</volume><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1177/2047487320906305</pub-id><pub-id pub-id-type="pmid">33838036</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>N</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Butt</surname><given-names>J</given-names></name><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Prager</surname><given-names>K</given-names></name><name><surname>Brozy</surname><given-names>J</given-names></name><name><surname>Weißbrich</surname><given-names>B</given-names></name><name><surname>Aiello</surname><given-names>AE</given-names></name><name><surname>Meier</surname><given-names>HCS</given-names></name><name><surname>Breuer</surname><given-names>J</given-names></name><name><surname>Almond</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>N</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Validation of multiplex serology detecting human herpesviruses 1-5</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0209379</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0209379</pub-id><pub-id pub-id-type="pmid">30589867</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>N</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Butt</surname><given-names>J</given-names></name><name><surname>Braband</surname><given-names>KL</given-names></name><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Jeffery</surname><given-names>K</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Gärtner</surname><given-names>B</given-names></name><name><surname>Schnitzler</surname><given-names>P</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>G</given-names></name><name><surname>Demontis</surname><given-names>MA</given-names></name><name><surname>Guy</surname><given-names>E</given-names></name><name><surname>Hadfield</surname><given-names>SJ</given-names></name><name><surname>Almond</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>N</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Validation of multiplex serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and <italic>Toxoplasma gondii</italic></article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0210407</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0210407</pub-id><pub-id pub-id-type="pmid">30615688</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>N</given-names></name><name><surname>Butt</surname><given-names>J</given-names></name><name><surname>Bomfim</surname><given-names>IL</given-names></name><name><surname>Tabatabai</surname><given-names>J</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Schnitzler</surname><given-names>P</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Validation of monoplex assays detecting antibodies against corynebacterium diphtheriae and clostridium tetani toxins, rubella virus and parvovirus B19 for incorporation into multiplex serology</article-title><source>Methods</source><volume>158</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2019.01.013</pub-id><pub-id pub-id-type="pmid">30703462</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>J</given-names></name><name><surname>Romero-Hernández</surname><given-names>B</given-names></name><name><surname>Pérez-Gómez</surname><given-names>B</given-names></name><name><surname>Willhauck-Fleckenstein</surname><given-names>M</given-names></name><name><surname>Holzinger</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>V</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><name><surname>Linares</surname><given-names>C</given-names></name><name><surname>Dierssen-Sotos</surname><given-names>T</given-names></name><name><surname>Barricarte</surname><given-names>A</given-names></name><name><surname>Tardón</surname><given-names>A</given-names></name><name><surname>Altzibar</surname><given-names>JM</given-names></name><name><surname>Moreno-Osset</surname><given-names>E</given-names></name><name><surname>Franco</surname><given-names>F</given-names></name><name><surname>Requena</surname><given-names>RO</given-names></name><name><surname>Huerta</surname><given-names>JM</given-names></name><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Castaño-Vinyals</surname><given-names>G</given-names></name><name><surname>Kogevinas</surname><given-names>M</given-names></name><name><surname>Pollán</surname><given-names>M</given-names></name><name><surname>Boleij</surname><given-names>A</given-names></name><name><surname>de Sanjosé</surname><given-names>S</given-names></name><name><surname>Del Campo</surname><given-names>R</given-names></name><name><surname>Tjalsma</surname><given-names>H</given-names></name><name><surname>Aragonés</surname><given-names>N</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Association of streptococcus gallolyticus subspecies gallolyticus with colorectal cancer: serological evidence</article-title><source>International Journal of Cancer</source><volume>138</volume><fpage>1670</fpage><lpage>1679</lpage><pub-id pub-id-type="doi">10.1002/ijc.29914</pub-id><pub-id pub-id-type="pmid">26537841</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>J</given-names></name><name><surname>Werner</surname><given-names>S</given-names></name><name><surname>Willhauck-Fleckenstein</surname><given-names>M</given-names></name><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Zörnig</surname><given-names>I</given-names></name><name><surname>Boleij</surname><given-names>A</given-names></name><name><surname>Dramsi</surname><given-names>S</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Serology of streptococcus gallolyticus subspecies gallolyticus and its association with colorectal cancer and precursors</article-title><source>International Journal of Cancer</source><volume>141</volume><fpage>897</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1002/ijc.30765</pub-id><pub-id pub-id-type="pmid">28477334</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>J</given-names></name><name><surname>Jenab</surname><given-names>M</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Tjonneland</surname><given-names>A</given-names></name><name><surname>Olsen</surname><given-names>A</given-names></name><name><surname>Boutron-Ruault</surname><given-names>M-C</given-names></name><name><surname>Carbonnel</surname><given-names>F</given-names></name><name><surname>Mancini</surname><given-names>FR</given-names></name><name><surname>Kaaks</surname><given-names>R</given-names></name><name><surname>Kühn</surname><given-names>T</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Karakatsani</surname><given-names>A</given-names></name><name><surname>Palli</surname><given-names>D</given-names></name><name><surname>Pala</surname><given-names>VM</given-names></name><name><surname>Tumino</surname><given-names>R</given-names></name><name><surname>Sacerdote</surname><given-names>C</given-names></name><name><surname>Panico</surname><given-names>S</given-names></name><name><surname>Bueno-de-Mesquita</surname><given-names>B</given-names></name><name><surname>van Gils</surname><given-names>CH</given-names></name><name><surname>Vermeulen</surname><given-names>RCH</given-names></name><name><surname>Weiderpass</surname><given-names>E</given-names></name><name><surname>Quirós</surname><given-names>JR</given-names></name><name><surname>Duell</surname><given-names>EJ</given-names></name><name><surname>Sánchez</surname><given-names>M-J</given-names></name><name><surname>Dorronsoro</surname><given-names>M</given-names></name><name><surname>Huerta</surname><given-names>JM</given-names></name><name><surname>Ardanaz</surname><given-names>E</given-names></name><name><surname>Van Guelpen</surname><given-names>B</given-names></name><name><surname>Harlid</surname><given-names>S</given-names></name><name><surname>Perez-Cornago</surname><given-names>A</given-names></name><name><surname>Gunter</surname><given-names>MJ</given-names></name><name><surname>Murphy</surname><given-names>N</given-names></name><name><surname>Freisling</surname><given-names>H</given-names></name><name><surname>Aune</surname><given-names>D</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Hughes</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Antibody responses to Fusobacterium nucleatum proteins in prediagnostic blood samples are not associated with risk of developing colorectal cancer</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>28</volume><fpage>1552</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-19-0313</pub-id><pub-id pub-id-type="pmid">31481495</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>LA</given-names></name><name><surname>Rosenfeld</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Infection and atherosclerosis development</article-title><source>Archives of Medical Research</source><volume>46</volume><fpage>339</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2015.05.006</pub-id><pub-id pub-id-type="pmid">26004263</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castelli</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Epidemiology of coronary heart disease: the framingham study</article-title><source>The American Journal of Medicine</source><volume>76</volume><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(84)90952-5</pub-id><pub-id pub-id-type="pmid">6702862</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SW</given-names></name><name><surname>Mak</surname><given-names>TS-H</given-names></name><name><surname>O’Reilly</surname><given-names>PF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tutorial: a guide to performing polygenic risk score analyses</article-title><source>Nature Protocols</source><volume>15</volume><fpage>2759</fpage><lpage>2772</lpage><pub-id pub-id-type="doi">10.1038/s41596-020-0353-1</pub-id><pub-id pub-id-type="pmid">32709988</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conroy</surname><given-names>RM</given-names></name><name><surname>Pyörälä</surname><given-names>K</given-names></name><name><surname>Fitzgerald</surname><given-names>AP</given-names></name><name><surname>Sans</surname><given-names>S</given-names></name><name><surname>Menotti</surname><given-names>A</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name><name><surname>Ducimetière</surname><given-names>P</given-names></name><name><surname>Jousilahti</surname><given-names>P</given-names></name><name><surname>Keil</surname><given-names>U</given-names></name><name><surname>Njølstad</surname><given-names>I</given-names></name><name><surname>Oganov</surname><given-names>RG</given-names></name><name><surname>Thomsen</surname><given-names>T</given-names></name><name><surname>Tunstall-Pedoe</surname><given-names>H</given-names></name><name><surname>Tverdal</surname><given-names>A</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name><name><surname>Whincup</surname><given-names>P</given-names></name><name><surname>Wilhelmsen</surname><given-names>L</given-names></name><name><surname>Graham</surname><given-names>IM</given-names></name><collab>SCORE project group</collab></person-group><year iso-8601-date="2003">2003</year><article-title>Estimation of ten-year risk of fatal cardiovascular disease in europe: the score project</article-title><source>European Heart Journal</source><volume>24</volume><fpage>987</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1016/s0195-668x(03)00114-3</pub-id><pub-id pub-id-type="pmid">12788299</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corredor</surname><given-names>Z</given-names></name><name><surname>Suarez-Molina</surname><given-names>A</given-names></name><name><surname>Fong</surname><given-names>C</given-names></name><name><surname>Cifuentes-C</surname><given-names>L</given-names></name><name><surname>Guauque-Olarte</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Presence of periodontal pathogenic bacteria in blood of patients with coronary artery disease</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>1241</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-05337-1</pub-id><pub-id pub-id-type="pmid">35075206</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>K</given-names></name><name><surname>Bailey</surname><given-names>KR</given-names></name><name><surname>Kullo</surname><given-names>IJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Genotype-informed estimation of risk of coronary heart disease based on genome-wide association data linked to the electronic medical record</article-title><source>BMC Cardiovascular Disorders</source><volume>11</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/1471-2261-11-66</pub-id><pub-id pub-id-type="pmid">22151179</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkaïm</surname><given-names>R</given-names></name><name><surname>Dahan</surname><given-names>M</given-names></name><name><surname>Kocgozlu</surname><given-names>L</given-names></name><name><surname>Werner</surname><given-names>S</given-names></name><name><surname>Kanter</surname><given-names>D</given-names></name><name><surname>Kretz</surname><given-names>JG</given-names></name><name><surname>Tenenbaum</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Prevalence of periodontal pathogens in subgingival lesions, atherosclerotic plaques and healthy blood vessels: a preliminary study</article-title><source>Journal of Periodontal Research</source><volume>43</volume><fpage>224</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0765.2007.01018.x</pub-id><pub-id pub-id-type="pmid">18326058</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engdahl</surname><given-names>E</given-names></name><name><surname>Gustafsson</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Biström</surname><given-names>M</given-names></name><name><surname>Lima Bomfim</surname><given-names>I</given-names></name><name><surname>Stridh</surname><given-names>P</given-names></name><name><surname>Khademi</surname><given-names>M</given-names></name><name><surname>Brenner</surname><given-names>N</given-names></name><name><surname>Butt</surname><given-names>J</given-names></name><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Jons</surname><given-names>D</given-names></name><name><surname>Hortlund</surname><given-names>M</given-names></name><name><surname>Alonso-Magdalena</surname><given-names>L</given-names></name><name><surname>Hedström</surname><given-names>AK</given-names></name><name><surname>Flamand</surname><given-names>L</given-names></name><name><surname>Ihira</surname><given-names>M</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Andersen</surname><given-names>O</given-names></name><name><surname>Hillert</surname><given-names>J</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Sundström</surname><given-names>P</given-names></name><name><surname>Olsson</surname><given-names>T</given-names></name><name><surname>Kockum</surname><given-names>I</given-names></name><name><surname>Fogdell-Hahn</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Increased serological response against human herpesvirus 6a is associated with risk for multiple sclerosis</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>2715</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02715</pub-id><pub-id pub-id-type="pmid">32038605</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figuero</surname><given-names>E</given-names></name><name><surname>Sánchez-Beltrán</surname><given-names>M</given-names></name><name><surname>Cuesta-Frechoso</surname><given-names>S</given-names></name><name><surname>Tejerina</surname><given-names>JM</given-names></name><name><surname>del Castro</surname><given-names>JA</given-names></name><name><surname>Gutiérrez</surname><given-names>JM</given-names></name><name><surname>Herrera</surname><given-names>D</given-names></name><name><surname>Sanz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Detection of periodontal bacteria in atheromatous plaque by nested polymerase chain reaction</article-title><source>Journal of Periodontology</source><volume>82</volume><fpage>1469</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1902/jop.2011.100719</pub-id><pub-id pub-id-type="pmid">21453047</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filardo</surname><given-names>S</given-names></name><name><surname>Di Pietro</surname><given-names>M</given-names></name><name><surname>Farcomeni</surname><given-names>A</given-names></name><name><surname>Schiavoni</surname><given-names>G</given-names></name><name><surname>Sessa</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chlamydia pneumoniae-mediated inflammation in atherosclerosis: a meta-analysis</article-title><source>Mediators of Inflammation</source><volume>2015</volume><elocation-id>378658</elocation-id><pub-id pub-id-type="doi">10.1155/2015/378658</pub-id><pub-id pub-id-type="pmid">26346892</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firmann</surname><given-names>M</given-names></name><name><surname>Mayor</surname><given-names>V</given-names></name><name><surname>Vidal</surname><given-names>PM</given-names></name><name><surname>Bochud</surname><given-names>M</given-names></name><name><surname>Pécoud</surname><given-names>A</given-names></name><name><surname>Hayoz</surname><given-names>D</given-names></name><name><surname>Paccaud</surname><given-names>F</given-names></name><name><surname>Preisig</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>KS</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Danoff</surname><given-names>TM</given-names></name><name><surname>Stirnadel</surname><given-names>HA</given-names></name><name><surname>Waterworth</surname><given-names>D</given-names></name><name><surname>Mooser</surname><given-names>V</given-names></name><name><surname>Waeber</surname><given-names>G</given-names></name><name><surname>Vollenweider</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The colaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome</article-title><source>BMC Cardiovascular Disorders</source><volume>8</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/1471-2261-8-6</pub-id><pub-id pub-id-type="pmid">18366642</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>PJ</given-names></name><name><surname>Gemmell</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Carter</surname><given-names>CL</given-names></name><name><surname>Walker</surname><given-names>PJ</given-names></name><name><surname>Bird</surname><given-names>PS</given-names></name><name><surname>West</surname><given-names>MJ</given-names></name><name><surname>Cullinan</surname><given-names>MP</given-names></name><name><surname>Seymour</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inflammation, heat shock proteins and periodontal pathogens in atherosclerosis: an immunohistologic study</article-title><source>Oral Microbiology and Immunology</source><volume>21</volume><fpage>206</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1111/j.1399-302X.2006.00276.x</pub-id><pub-id pub-id-type="pmid">16842503</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freuer</surname><given-names>D</given-names></name><name><surname>Linseisen</surname><given-names>J</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Pessler</surname><given-names>F</given-names></name><name><surname>Guzmán</surname><given-names>CA</given-names></name><name><surname>Wawro</surname><given-names>N</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Meisinger</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Seropositivity of selected chronic infections and different measures of obesity</article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0231974</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0231974</pub-id><pub-id pub-id-type="pmid">32320435</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>A</given-names></name><name><surname>Lion</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1889">1889</year><article-title>Arterites infectieuses experimentales</article-title><source>Comptes Rendus Hebdomadaires Des Séances et Mémoires de La Societé de Biologie</source><volume>41</volume><fpage>583</fpage><lpage>584</lpage></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gossai</surname><given-names>A</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Nelson</surname><given-names>HH</given-names></name><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Willhauck-Fleckenstein</surname><given-names>M</given-names></name><name><surname>Farzan</surname><given-names>SF</given-names></name><name><surname>Hoen</surname><given-names>AG</given-names></name><name><surname>Christensen</surname><given-names>BC</given-names></name><name><surname>Kelsey</surname><given-names>KT</given-names></name><name><surname>Marsit</surname><given-names>CJ</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Karagas</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Seroepidemiology of human polyomaviruses in a US population</article-title><source>American Journal of Epidemiology</source><volume>183</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1093/aje/kwv155</pub-id><pub-id pub-id-type="pmid">26667254</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>YW</given-names></name><name><surname>Redline</surname><given-names>RW</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Hill</surname><given-names>GB</given-names></name><name><surname>McCormick</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Fusobacterium nucleatum induces premature and term stillbirths in pregnant mice: implication of oral bacteria in preterm birth</article-title><source>Infection and Immunity</source><volume>72</volume><fpage>2272</fpage><lpage>2279</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.4.2272-2279.2004</pub-id><pub-id pub-id-type="pmid">15039352</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>YW</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mobile microbiome: oral bacteria in extra-oral infections and inflammation</article-title><source>Journal of Dental Research</source><volume>92</volume><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1177/0022034513487559</pub-id><pub-id pub-id-type="pmid">23625375</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>YW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fusobacterium nucleatum: a commensal-turned pathogen</article-title><source>Current Opinion in Microbiology</source><volume>23</volume><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2014.11.013</pub-id><pub-id pub-id-type="pmid">25576662</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Inflammation, atherosclerosis, and coronary artery disease</article-title><source>The New England Journal of Medicine</source><volume>352</volume><fpage>1685</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1056/NEJMra043430</pub-id><pub-id pub-id-type="pmid">15843671</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodel</surname><given-names>F</given-names></name><name><surname>Chong</surname><given-names>AY</given-names></name><name><surname>Scepanovic</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>ZM</given-names></name><name><surname>Naret</surname><given-names>O</given-names></name><name><surname>Thorball</surname><given-names>CW</given-names></name><name><surname>Rüeger</surname><given-names>S</given-names></name><name><surname>Marques-Vidal</surname><given-names>P</given-names></name><name><surname>Vollenweider</surname><given-names>P</given-names></name><name><surname>Begemann</surname><given-names>M</given-names></name><name><surname>Ehrenreich</surname><given-names>H</given-names></name><name><surname>Brenner</surname><given-names>N</given-names></name><name><surname>Bender</surname><given-names>N</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Hill</surname><given-names>AVS</given-names></name><name><surname>Hammer</surname><given-names>C</given-names></name><name><surname>Fellay</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Human genomics of the humoral immune response against polyomaviruses</article-title><source>Virus Evolution</source><volume>7</volume><elocation-id>veab058</elocation-id><pub-id pub-id-type="doi">10.1093/ve/veab058</pub-id><pub-id pub-id-type="pmid">34532061</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inouye</surname><given-names>M</given-names></name><name><surname>Abraham</surname><given-names>G</given-names></name><name><surname>Nelson</surname><given-names>CP</given-names></name><name><surname>Wood</surname><given-names>AM</given-names></name><name><surname>Sweeting</surname><given-names>MJ</given-names></name><name><surname>Dudbridge</surname><given-names>F</given-names></name><name><surname>Lai</surname><given-names>FY</given-names></name><name><surname>Kaptoge</surname><given-names>S</given-names></name><name><surname>Brozynska</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Webb</surname><given-names>TR</given-names></name><name><surname>Rutter</surname><given-names>MK</given-names></name><name><surname>Tzoulaki</surname><given-names>I</given-names></name><name><surname>Patel</surname><given-names>RS</given-names></name><name><surname>Loos</surname><given-names>RJF</given-names></name><name><surname>Keavney</surname><given-names>B</given-names></name><name><surname>Hemingway</surname><given-names>H</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Di Angelantonio</surname><given-names>E</given-names></name><name><surname>Butterworth</surname><given-names>AS</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><collab>UK Biobank CardioMetabolic Consortium CHD Working Group</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention</article-title><source>Journal of the American College of Cardiology</source><volume>72</volume><fpage>1883</fpage><lpage>1893</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2018.07.079</pub-id><pub-id pub-id-type="pmid">30309464</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kholy</surname><given-names>KE</given-names></name><name><surname>Genco</surname><given-names>RJ</given-names></name><name><surname>Van Dyke</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Oral infections and cardiovascular disease</article-title><source>Trends in Endocrinology and Metabolism</source><volume>26</volume><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2015.03.001</pub-id><pub-id pub-id-type="pmid">25892452</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khot</surname><given-names>UN</given-names></name><name><surname>Khot</surname><given-names>MB</given-names></name><name><surname>Bajzer</surname><given-names>CT</given-names></name><name><surname>Sapp</surname><given-names>SK</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Brener</surname><given-names>SJ</given-names></name><name><surname>Ellis</surname><given-names>SG</given-names></name><name><surname>Lincoff</surname><given-names>AM</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Prevalence of conventional risk factors in patients with coronary heart disease</article-title><source>JAMA</source><volume>290</volume><fpage>898</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1001/jama.290.7.898</pub-id><pub-id pub-id-type="pmid">12928466</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjaerheim</surname><given-names>K</given-names></name><name><surname>Røe</surname><given-names>OD</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Sehr</surname><given-names>P</given-names></name><name><surname>Rizk</surname><given-names>R</given-names></name><name><surname>Dai</surname><given-names>HY</given-names></name><name><surname>Sandeck</surname><given-names>H</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Andersen</surname><given-names>A</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples</article-title><source>International Journal of Cancer</source><volume>120</volume><fpage>2459</fpage><lpage>2465</lpage><pub-id pub-id-type="doi">10.1002/ijc.22592</pub-id><pub-id pub-id-type="pmid">17315193</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kullo</surname><given-names>IJ</given-names></name><name><surname>Jouni</surname><given-names>H</given-names></name><name><surname>Austin</surname><given-names>EE</given-names></name><name><surname>Brown</surname><given-names>S-A</given-names></name><name><surname>Kruisselbrink</surname><given-names>TM</given-names></name><name><surname>Isseh</surname><given-names>IN</given-names></name><name><surname>Haddad</surname><given-names>RA</given-names></name><name><surname>Marroush</surname><given-names>TS</given-names></name><name><surname>Shameer</surname><given-names>K</given-names></name><name><surname>Olson</surname><given-names>JE</given-names></name><name><surname>Broeckel</surname><given-names>U</given-names></name><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name><name><surname>Bailey</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Incorporating a genetic risk score into coronary heart disease risk estimates: effect on low-density lipoprotein cholesterol levels (the mi-genes clinical trial)</article-title><source>Circulation</source><volume>133</volume><fpage>1181</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.020109</pub-id><pub-id pub-id-type="pmid">26915630</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>SA</given-names></name><name><surname>Gil</surname><given-names>L</given-names></name><name><surname>Jupp</surname><given-names>S</given-names></name><name><surname>Ritchie</surname><given-names>SC</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Buniello</surname><given-names>A</given-names></name><name><surname>McMahon</surname><given-names>A</given-names></name><name><surname>Abraham</surname><given-names>G</given-names></name><name><surname>Chapman</surname><given-names>M</given-names></name><name><surname>Parkinson</surname><given-names>H</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>MacArthur</surname><given-names>JAL</given-names></name><name><surname>Inouye</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The polygenic score catalog as an open database for reproducibility and systematic evaluation</article-title><source>Nature Genetics</source><volume>53</volume><fpage>420</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00783-5</pub-id><pub-id pub-id-type="pmid">33692568</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inflammation and cardiovascular disease mechanisms</article-title><source>The American Journal of Clinical Nutrition</source><volume>83</volume><fpage>456S</fpage><lpage>460S</lpage><pub-id pub-id-type="doi">10.1093/ajcn/83.2.456S</pub-id><pub-id pub-id-type="pmid">16470012</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Looker</surname><given-names>KJ</given-names></name><name><surname>Magaret</surname><given-names>AS</given-names></name><name><surname>May</surname><given-names>MT</given-names></name><name><surname>Turner</surname><given-names>KME</given-names></name><name><surname>Vickerman</surname><given-names>P</given-names></name><name><surname>Gottlieb</surname><given-names>SL</given-names></name><name><surname>Newman</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0140765</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0140765</pub-id><pub-id pub-id-type="pmid">26510007</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>Cutler</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Sorlie</surname><given-names>P</given-names></name><name><surname>Neaton</surname><given-names>J</given-names></name><name><surname>Abbott</surname><given-names>R</given-names></name><name><surname>Godwin</surname><given-names>J</given-names></name><name><surname>Dyer</surname><given-names>A</given-names></name><name><surname>Stamler</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias</article-title><source>Lancet</source><volume>335</volume><fpage>765</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(90)90878-9</pub-id><pub-id pub-id-type="pmid">1969518</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marenberg</surname><given-names>ME</given-names></name><name><surname>Risch</surname><given-names>N</given-names></name><name><surname>Berkman</surname><given-names>LF</given-names></name><name><surname>Floderus</surname><given-names>B</given-names></name><name><surname>de Faire</surname><given-names>U</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Genetic susceptibility to death from coronary heart disease in a study of twins</article-title><source>The New England Journal of Medicine</source><volume>330</volume><fpage>1041</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1056/NEJM199404143301503</pub-id><pub-id pub-id-type="pmid">8127331</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques-Vidal</surname><given-names>P</given-names></name><name><surname>Bochud</surname><given-names>M</given-names></name><name><surname>Bastardot</surname><given-names>F</given-names></name><name><surname>Lüscher</surname><given-names>T</given-names></name><name><surname>Ferrero</surname><given-names>F</given-names></name><name><surname>Gaspoz</surname><given-names>J-M</given-names></name><name><surname>Paccaud</surname><given-names>F</given-names></name><name><surname>Urwyler</surname><given-names>A</given-names></name><name><surname>von Känel</surname><given-names>R</given-names></name><name><surname>Hock</surname><given-names>C</given-names></name><name><surname>Waeber</surname><given-names>G</given-names></name><name><surname>Preisig</surname><given-names>M</given-names></name><name><surname>Vollenweider</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Levels and determinants of inflammatory biomarkers in a Swiss population-based sample (colaus study)</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e21002</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0021002</pub-id><pub-id pub-id-type="pmid">21695270</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mendis</surname><given-names>S</given-names></name><name><surname>Puska</surname><given-names>P</given-names></name><name><surname>Norrving</surname><given-names>B e</given-names></name></person-group><year iso-8601-date="2011">2011</year><source>Global Atlas on Cardiovascular Disease Prevention and Control</source><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Kist</surname><given-names>M</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Helicobacter pylori multiplex serology</article-title><source>Helicobacter</source><volume>14</volume><fpage>525</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2009.00723.x</pub-id><pub-id pub-id-type="pmid">19889070</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1938">1938</year><article-title>Xanthomata, hypercholesterolemia, angina pectoris</article-title><source>Acta Medica Scandinavica</source><volume>95</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/j.0954-6820.1938.tb19279.x</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedicino</surname><given-names>D</given-names></name><name><surname>Giglio</surname><given-names>AF</given-names></name><name><surname>Galiffa</surname><given-names>VA</given-names></name><name><surname>Cialdella</surname><given-names>P</given-names></name><name><surname>Trotta</surname><given-names>F</given-names></name><name><surname>Graziani</surname><given-names>F</given-names></name><name><surname>Liuzzo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Infections, immunity and atherosclerosis: pathogenic mechanisms and unsolved questions</article-title><source>International Journal of Cardiology</source><volume>166</volume><fpage>572</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2012.05.098</pub-id><pub-id pub-id-type="pmid">22727974</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robles</surname><given-names>C</given-names></name><name><surname>Casabonne</surname><given-names>D</given-names></name><name><surname>Benavente</surname><given-names>Y</given-names></name><name><surname>Costas</surname><given-names>L</given-names></name><name><surname>Gonzalez-Barca</surname><given-names>E</given-names></name><name><surname>Aymerich</surname><given-names>M</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Tardon</surname><given-names>A</given-names></name><name><surname>Jiménez-Moleón</surname><given-names>JJ</given-names></name><name><surname>Castaño-Vinyals</surname><given-names>G</given-names></name><name><surname>Dierssen-Sotos</surname><given-names>T</given-names></name><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Kranz</surname><given-names>L</given-names></name><name><surname>Aragonés</surname><given-names>N</given-names></name><name><surname>Pollan</surname><given-names>M</given-names></name><name><surname>Kogevinas</surname><given-names>M</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>de Sanjose</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Seroreactivity against Merkel cell polyomavirus and other polyomaviruses in chronic lymphocytic leukaemia, the mcc-spain study</article-title><source>The Journal of General Virology</source><volume>96</volume><fpage>2286</fpage><lpage>2292</lpage><pub-id pub-id-type="doi">10.1099/vir.0.000167</pub-id><pub-id pub-id-type="pmid">25920529</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>GA</given-names></name><name><surname>Abate</surname><given-names>D</given-names></name><name><surname>Abate</surname><given-names>KH</given-names></name><name><surname>Abay</surname><given-names>SM</given-names></name><name><surname>Abbafati</surname><given-names>C</given-names></name><name><surname>Abbasi</surname><given-names>N</given-names></name><name><surname>Abbastabar</surname><given-names>H</given-names></name><name><surname>Abd-Allah</surname><given-names>F</given-names></name><name><surname>Abdela</surname><given-names>J</given-names></name><name><surname>Abdelalim</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017</article-title><source>Lancet</source><volume>392</volume><fpage>1736</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32203-7</pub-id><pub-id pub-id-type="pmid">30496103</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saikku</surname><given-names>P</given-names></name><name><surname>Leinonen</surname><given-names>M</given-names></name><name><surname>Mattila</surname><given-names>K</given-names></name><name><surname>Ekman</surname><given-names>MR</given-names></name><name><surname>Nieminen</surname><given-names>MS</given-names></name><name><surname>Mäkelä</surname><given-names>PH</given-names></name><name><surname>Huttunen</surname><given-names>JK</given-names></name><name><surname>Valtonen</surname><given-names>V</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction</article-title><source>Lancet</source><volume>2</volume><fpage>983</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(88)90741-6</pub-id><pub-id pub-id-type="pmid">2902492</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Erdmann</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>AS</given-names></name><name><surname>Hengstenberg</surname><given-names>C</given-names></name><name><surname>Mangino</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>B</given-names></name><name><surname>Dixon</surname><given-names>RJ</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Braund</surname><given-names>P</given-names></name><name><surname>Wichmann</surname><given-names>H-E</given-names></name><name><surname>Barrett</surname><given-names>JH</given-names></name><name><surname>König</surname><given-names>IR</given-names></name><name><surname>Stevens</surname><given-names>SE</given-names></name><name><surname>Szymczak</surname><given-names>S</given-names></name><name><surname>Tregouet</surname><given-names>D-A</given-names></name><name><surname>Iles</surname><given-names>MM</given-names></name><name><surname>Pahlke</surname><given-names>F</given-names></name><name><surname>Pollard</surname><given-names>H</given-names></name><name><surname>Lieb</surname><given-names>W</given-names></name><name><surname>Cambien</surname><given-names>F</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Ouwehand</surname><given-names>W</given-names></name><name><surname>Blankenberg</surname><given-names>S</given-names></name><name><surname>Balmforth</surname><given-names>AJ</given-names></name><name><surname>Baessler</surname><given-names>A</given-names></name><name><surname>Ball</surname><given-names>SG</given-names></name><name><surname>Strom</surname><given-names>TM</given-names></name><name><surname>Braenne</surname><given-names>I</given-names></name><name><surname>Gieger</surname><given-names>C</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Tobin</surname><given-names>MD</given-names></name><name><surname>Ziegler</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>JR</given-names></name><name><surname>Schunkert</surname><given-names>H</given-names></name><collab>WTCCC and the Cardiogenics Consortium</collab></person-group><year iso-8601-date="2007">2007</year><article-title>Genomewide association analysis of coronary artery disease</article-title><source>The New England Journal of Medicine</source><volume>357</volume><fpage>443</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa072366</pub-id><pub-id pub-id-type="pmid">17634449</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>SCORE2-OP working group and ESC Cardiovascular risk collaboration</collab></person-group><year iso-8601-date="2021">2021</year><article-title>SCORE2-op risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions</article-title><source>European Heart Journal</source><volume>42</volume><fpage>2455</fpage><lpage>2467</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab312</pub-id><pub-id pub-id-type="pmid">34120185</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>SCORE2 working group and ESC Cardiovascular risk collaboration</collab></person-group><year iso-8601-date="2021">2021</year><article-title>SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in europe</article-title><source>European Heart Journal</source><volume>42</volume><fpage>2439</fpage><lpage>2454</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab309</pub-id><pub-id pub-id-type="pmid">34120177</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Vaccaro</surname><given-names>O</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Wentworth</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial</article-title><source>Diabetes Care</source><volume>16</volume><fpage>434</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.2337/diacare.16.2.434</pub-id><pub-id pub-id-type="pmid">8432214</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trabert</surname><given-names>B</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Idahl</surname><given-names>A</given-names></name><name><surname>Brenner</surname><given-names>N</given-names></name><name><surname>Brinton</surname><given-names>LA</given-names></name><name><surname>Butt</surname><given-names>J</given-names></name><name><surname>Coburn</surname><given-names>SB</given-names></name><name><surname>Hartge</surname><given-names>P</given-names></name><name><surname>Hufnagel</surname><given-names>K</given-names></name><name><surname>Inturrisi</surname><given-names>F</given-names></name><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Mentzer</surname><given-names>A</given-names></name><name><surname>Peplonska</surname><given-names>B</given-names></name><name><surname>Sherman</surname><given-names>ME</given-names></name><name><surname>Wills</surname><given-names>GS</given-names></name><name><surname>Woodhall</surname><given-names>SC</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name><name><surname>Wentzensen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Antibodies against <italic>Chlamydia trachomatis</italic> and ovarian cancer risk in two independent populations</article-title><source>Journal of the National Cancer Institute</source><volume>111</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1093/jnci/djy084</pub-id><pub-id pub-id-type="pmid">29790947</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verschuren</surname><given-names>WM</given-names></name><name><surname>Jacobs</surname><given-names>DR</given-names></name><name><surname>Bloemberg</surname><given-names>BP</given-names></name><name><surname>Kromhout</surname><given-names>D</given-names></name><name><surname>Menotti</surname><given-names>A</given-names></name><name><surname>Aravanis</surname><given-names>C</given-names></name><name><surname>Blackburn</surname><given-names>H</given-names></name><name><surname>Buzina</surname><given-names>R</given-names></name><name><surname>Dontas</surname><given-names>AS</given-names></name><name><surname>Fidanza</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study</article-title><source>JAMA</source><volume>274</volume><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1001/jama.1995.03530020049031</pub-id><pub-id pub-id-type="pmid">7596000</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinkhuyzen</surname><given-names>AAE</given-names></name><name><surname>Wray</surname><given-names>NR</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Goddard</surname><given-names>ME</given-names></name><name><surname>Visscher</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Estimation and partition of heritability in human populations using whole-genome analysis methods</article-title><source>Annual Review of Genetics</source><volume>47</volume><fpage>75</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-111212-133258</pub-id><pub-id pub-id-type="pmid">23988118</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vojdani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A look at infectious agents as a possible causative factor in cardiovascular disease: Part I</article-title><source>Laboratory Medicine</source><volume>34</volume><fpage>203</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1309/0428W4EFE7J6YT40</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A meta-analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease</article-title><source>Helicobacter</source><volume>25</volume><elocation-id>e12761</elocation-id><pub-id pub-id-type="doi">10.1111/hel.12761</pub-id><pub-id pub-id-type="pmid">33026704</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Sehr</surname><given-names>P</given-names></name><name><surname>Michael</surname><given-names>KM</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Nieland</surname><given-names>JD</given-names></name><name><surname>Joos</surname><given-names>TO</given-names></name><name><surname>Templin</surname><given-names>MF</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins</article-title><source>Clinical Chemistry</source><volume>51</volume><fpage>1845</fpage><lpage>1853</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2005.052381</pub-id><pub-id pub-id-type="pmid">16099939</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Sehr</surname><given-names>P</given-names></name><name><surname>Pawlita</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Suppression of non-specific binding in serological luminex assays</article-title><source>Journal of Immunological Methods</source><volume>309</volume><fpage>200</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2005.11.008</pub-id><pub-id pub-id-type="pmid">16406059</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>WS</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Cigarette smoking as a risk factor for coronary artery disease</article-title><source>Advances in Experimental Medicine and Biology</source><volume>273</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/978-1-4684-5829-9_4</pub-id><pub-id pub-id-type="pmid">2288281</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2009">2009</year><article-title>Cardiovascular diseases (cvds)</article-title><ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs317/en/index.html">http://www.who.int/mediacentre/factsheets/fs317/en/index.html</ext-link><date-in-citation iso-8601-date="2022-02-24">February 24, 2022</date-in-citation></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zardawi</surname><given-names>F</given-names></name><name><surname>Gul</surname><given-names>S</given-names></name><name><surname>Abdulkareem</surname><given-names>A</given-names></name><name><surname>Sha</surname><given-names>A</given-names></name><name><surname>Yates</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Association between periodontal disease and atherosclerotic cardiovascular diseases: revisited</article-title><source>Frontiers in Cardiovascular Medicine</source><volume>7</volume><elocation-id>625579</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2020.625579</pub-id><pub-id pub-id-type="pmid">33521070</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Teng</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cytotoxin-associated gene-a-seropositive virulent strains of helicobacter pylori and atherosclerotic diseases: a systematic review</article-title><source>Chinese Medical Journal</source><volume>121</volume><fpage>946</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">18706211</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Additional tables</title><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Characteristics of infectious agent-specific antigens used on the Multiplex Serology platform in CoLaus|PsyCoLaus.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Family</th><th align="left" valign="bottom">Pathogen</th><th align="left" valign="bottom">Antigen</th><th align="left" valign="bottom">(Predicted) function</th><th align="left" valign="bottom">Def. of seropositivity is based on</th><th align="left" valign="bottom">Reference</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="4">Human polyomaviruses</td><td align="left" valign="bottom">BKV</td><td align="left" valign="bottom">VP1</td><td align="left" valign="bottom">Major capsid protein</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">Kjaerheim et al., 2007</xref>; <xref ref-type="bibr" rid="bib29">Gossai et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Robles et al., 2015</xref></td></tr><tr><td align="left" valign="bottom">JCV</td><td align="left" valign="bottom">VP1</td><td align="left" valign="bottom">Major capsid protein</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">Kjaerheim et al., 2007</xref>; <xref ref-type="bibr" rid="bib29">Gossai et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Robles et al., 2015</xref></td></tr><tr><td align="left" valign="bottom">HPyV6</td><td align="left" valign="bottom">VP1</td><td align="left" valign="bottom">Major capsid protein</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">Kjaerheim et al., 2007</xref>; <xref ref-type="bibr" rid="bib29">Gossai et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Robles et al., 2015</xref></td></tr><tr><td align="left" valign="bottom">WUPyV</td><td align="left" valign="bottom">VP1</td><td align="left" valign="bottom">Major capsid protein</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">Kjaerheim et al., 2007</xref>; <xref ref-type="bibr" rid="bib29">Gossai et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Robles et al., 2015</xref></td></tr><tr><td align="left" valign="bottom" rowspan="17">Human herpes viruses</td><td align="left" valign="bottom" rowspan="3">CMV</td><td align="left" valign="bottom">pp150</td><td align="left" valign="bottom">Tegument protein</td><td align="left" valign="bottom" rowspan="3">At least two positive</td><td align="left" valign="bottom" rowspan="3"><xref ref-type="bibr" rid="bib9">Brenner et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">pp52</td><td align="left" valign="bottom">DNA binding protein</td></tr><tr><td align="left" valign="bottom">pp28</td><td align="left" valign="bottom">Capsid protein</td></tr><tr><td align="left" valign="bottom" rowspan="4">EBV</td><td align="left" valign="bottom">ZEBRA</td><td align="left" valign="bottom">Replication activator</td><td align="left" valign="bottom" rowspan="4">At least two positive</td><td align="left" valign="bottom" rowspan="4"><xref ref-type="bibr" rid="bib9">Brenner et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">EA-D</td><td align="left" valign="bottom">Replication (polymerase accessory subunit)</td></tr><tr><td align="left" valign="bottom">VCA p18</td><td align="left" valign="bottom">Capsid protein</td></tr><tr><td align="left" valign="bottom">EBNA1</td><td align="left" valign="bottom">Replication, latent viral infection</td></tr><tr><td align="left" valign="bottom" rowspan="4">HHV-6</td><td align="left" valign="bottom">IE1B</td><td align="left" valign="bottom">Potential transactivator</td><td align="left" valign="bottom" rowspan="4">Any HHV-6=at least one positive HHV-6A=IE1A and/or p100HHV-6B=IE1B and/or p101K</td><td align="char" char="." valign="bottom" rowspan="4"><xref ref-type="bibr" rid="bib7">Bassig et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">Engdahl et al., 2019</xref>; <xref ref-type="bibr" rid="bib27">Freuer et al., 2020</xref></td></tr><tr><td align="left" valign="bottom">IE1A</td><td align="left" valign="bottom">Potential transactivator</td></tr><tr><td align="left" valign="bottom">p101K</td><td align="left" valign="bottom">Potential tegument protein</td></tr><tr><td align="left" valign="bottom">p100</td><td align="left" valign="bottom">Potential tegument protein</td></tr><tr><td align="left" valign="bottom">HHV-7</td><td align="left" valign="bottom">U14</td><td align="left" valign="bottom">Potential tegument protein</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">Validation ongoing</td></tr><tr><td align="left" valign="bottom">HSV-1</td><td align="left" valign="bottom">gG</td><td align="left" valign="bottom">Membrane glycoprotein</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib10">Brenner et al., 2019a</xref></td></tr><tr><td align="left" valign="bottom">HSV-2</td><td align="left" valign="bottom">mgG</td><td align="left" valign="bottom">Membrane glycoprotein</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib10">Brenner et al., 2019a</xref></td></tr><tr><td align="left" valign="bottom" rowspan="2">KSHV</td><td align="left" valign="bottom">LANA3</td><td align="left" valign="bottom">Replication and long-term persistence</td><td align="left" valign="bottom" rowspan="2">At least one positive</td><td align="left" valign="bottom" rowspan="2">Validation ongoing</td></tr><tr><td align="left" valign="bottom">K8.1</td><td align="left" valign="bottom">Structural glycoprotein</td></tr><tr><td align="left" valign="bottom">VZV</td><td align="left" valign="bottom">gE/gI</td><td align="left" valign="bottom">Envelope glycoprotein</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib10">Brenner et al., 2019a</xref></td></tr><tr><td align="left" valign="bottom">Parvovirus</td><td align="left" valign="bottom">B19</td><td align="left" valign="bottom">VP1unique</td><td align="left" valign="bottom">Minor capsid protein</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib11">Brenner et al., 2019b</xref></td></tr><tr><td align="left" valign="bottom">Rubella virus<xref ref-type="table-fn" rid="app1table1fn1">*</xref></td><td align="left" valign="bottom">RV</td><td align="left" valign="bottom">E1</td><td align="left" valign="bottom">Class II viral fusion protein</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib11">Brenner et al., 2019b</xref></td></tr><tr><td align="left" valign="bottom"><italic>C. trachomatis</italic></td><td align="left" valign="bottom">Ct</td><td align="left" valign="bottom">pGP3</td><td align="left" valign="bottom">Virulence factor</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib57">Trabert et al., 2019</xref></td></tr><tr><td align="left" valign="bottom"><italic>C. tetani</italic><xref ref-type="table-fn" rid="app1table1fn1">*</xref></td><td align="left" valign="bottom">Ct</td><td align="left" valign="bottom">TetX</td><td align="left" valign="bottom">Toxoid (heavy chain)</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib11">Brenner et al., 2019b</xref></td></tr><tr><td align="left" valign="bottom"><italic>Corynebacterium diphtheriae</italic><xref ref-type="table-fn" rid="app1table1fn1">*</xref></td><td align="left" valign="bottom">Cd</td><td align="left" valign="bottom">DTA</td><td align="left" valign="bottom">Toxoid (intracellular)</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib11">Brenner et al., 2019b</xref></td></tr><tr><td align="left" valign="bottom" rowspan="3"><italic>F. nucleatum</italic></td><td align="left" valign="bottom" rowspan="3">Fn</td><td align="left" valign="bottom">Fn0264</td><td align="left" valign="bottom">Adhesin (FadA)</td><td align="left" valign="bottom" rowspan="3">At least one positive (experimental)</td><td align="char" char="." valign="bottom" rowspan="3"><xref ref-type="bibr" rid="bib14">Butt et al., 2019</xref></td></tr><tr><td align="left" valign="bottom">Fn1449</td><td align="left" valign="bottom">Type Va secretion system (Fap2)</td></tr><tr><td align="left" valign="bottom">Fn1859</td><td align="left" valign="bottom">Porin (FomA)</td></tr><tr><td align="left" valign="bottom" rowspan="6"><italic>H. pylori</italic></td><td align="left" valign="bottom" rowspan="6">Hp</td><td align="left" valign="bottom">HP 10 GroEL</td><td align="left" valign="bottom">Chaperonin</td><td align="left" valign="bottom" rowspan="6">At least three positive</td><td align="char" char="." valign="bottom" rowspan="6"><xref ref-type="bibr" rid="bib47">Michel et al., 2009</xref></td></tr><tr><td align="left" valign="bottom">HP 73 UreaseA</td><td align="left" valign="bottom">Urease alpha subunit</td></tr><tr><td align="left" valign="bottom">HP 547 CagA</td><td align="left" valign="bottom">Pathogenesis</td></tr><tr><td align="left" valign="bottom">HP 875 Catalase</td><td align="left" valign="bottom">Detoxification</td></tr><tr><td align="left" valign="bottom">HP 887 VacA</td><td align="left" valign="bottom">Pathogenesis</td></tr><tr><td align="left" valign="bottom">HP 1564 OMP</td><td align="left" valign="bottom">Cell envelope</td></tr><tr><td align="left" valign="bottom"><italic>S. gallolyticus</italic></td><td align="left" valign="bottom">Sg</td><td align="left" valign="bottom">Gallo2178</td><td align="left" valign="bottom"><italic>Pil1 pilus subunit (major pilin</italic>)</td><td align="left" valign="bottom">NA</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib12">Butt et al., 2016</xref>; <xref ref-type="bibr" rid="bib13">Butt et al., 2017</xref></td></tr><tr><td align="left" valign="bottom" rowspan="2"><italic>T. gondii</italic></td><td align="left" valign="bottom" rowspan="2">Tg</td><td align="left" valign="bottom">p22</td><td align="left" valign="bottom">Surface protein</td><td align="left" valign="bottom" rowspan="2">At least one positive</td><td align="char" char="." valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib10">Brenner et al., 2019a</xref></td></tr><tr><td align="left" valign="bottom">sag-1</td><td align="left" valign="bottom">Surface protein</td></tr></tbody></table><table-wrap-foot><fn id="app1table1fn1"><label>*</label><p>Pathogens not taken forward due to lack of vaccination history in CoLaus|PsyCoLaus and/or the difficulty in identifying target antigens to ensure specificity of the test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>Association of risk factors with coronary heart disease (CHD) based on the univariable Cox proportional hazard analyses.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variable</th><th align="left" valign="bottom">HR* (95% CI)<xref ref-type="table-fn" rid="app1table2fn1">*</xref></th><th align="left" valign="bottom">p</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Baseline characteristics</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">SCORE2</td><td align="left" valign="bottom">1.72 (1.61–1.85)</td><td align="left" valign="bottom">2.87×10-61</td></tr><tr><td align="left" valign="bottom">Statin</td><td align="left" valign="bottom">3.82 (2.80–5.22)</td><td align="left" valign="bottom">3.13×10-17</td></tr><tr><td align="left" valign="bottom">Average gross monthly income</td><td align="left" valign="bottom">0.85 (0.76–0.96)</td><td align="left" valign="bottom">7.27×10-3</td></tr><tr><td align="left" valign="bottom"><bold>Genetics</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">CHD-PRS</td><td align="left" valign="bottom">1.32 (1.16–1.51)</td><td align="left" valign="bottom">4.29×10-5</td></tr><tr><td align="left" valign="bottom">PC1</td><td align="left" valign="bottom">74-28 (0.03–195096)</td><td align="left" valign="bottom">0.28</td></tr><tr><td align="left" valign="bottom">PC2</td><td align="left" valign="bottom">0.12 (00.0–728)</td><td align="left" valign="bottom">0.64</td></tr><tr><td align="left" valign="bottom">PC3</td><td align="left" valign="bottom">0.33 (0.00–1131)</td><td align="left" valign="bottom">0.79</td></tr><tr><td align="left" valign="bottom"><bold>Biomarkers of inflammation</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">hs-CRP<xref ref-type="table-fn" rid="app1table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">1.91 (1.42–2.55)</td><td align="left" valign="bottom">1.51×10-5</td></tr><tr><td align="left" valign="bottom">TNF-α<xref ref-type="table-fn" rid="app1table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">1.43 (1.05–1.96)</td><td align="left" valign="bottom">2.46×10-2</td></tr><tr><td align="left" valign="bottom">IL-1β<xref ref-type="table-fn" rid="app1table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">0.93 (0.70–1.25)</td><td align="left" valign="bottom">0.64</td></tr><tr><td align="left" valign="bottom">IL-6<xref ref-type="table-fn" rid="app1table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">1.10 (0.88–1.37)</td><td align="left" valign="bottom">0.42</td></tr><tr><td align="left" valign="bottom"><bold>Human polyomaviruses</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">BKPyV</td><td align="left" valign="bottom">1.05 (0.72–1.52)</td><td align="left" valign="bottom">0.80</td></tr><tr><td align="left" valign="bottom">JCPyV</td><td align="left" valign="bottom">1.14 (0.87–1.50)</td><td align="left" valign="bottom">0.35</td></tr><tr><td align="left" valign="bottom">HPyV6</td><td align="left" valign="bottom">1.66 (1.06–2.61)</td><td align="left" valign="bottom">2.74×10-2</td></tr><tr><td align="left" valign="bottom">WUPyV</td><td align="left" valign="bottom">1.45 (0.65–3.27)</td><td align="left" valign="bottom">0.37</td></tr><tr><td align="left" valign="bottom"><bold>Human herpes viruses</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">HSV-1</td><td align="left" valign="bottom">1.88 (1.30–2.68)</td><td align="left" valign="bottom">6.52×10-4</td></tr><tr><td align="left" valign="bottom">HSV-2</td><td align="left" valign="bottom">1.05 (0.74–1.50)</td><td align="left" valign="bottom">0.78</td></tr><tr><td align="left" valign="bottom">CMV</td><td align="left" valign="bottom">1.00 (0.76–1.31)</td><td align="left" valign="bottom">0.99</td></tr><tr><td align="left" valign="bottom">EBV</td><td align="left" valign="bottom">0.97 (0.46–2.06)</td><td align="left" valign="bottom">0.94</td></tr><tr><td align="left" valign="bottom">HHV-6A</td><td align="left" valign="bottom">1.39 (1.03–1.86)</td><td align="left" valign="bottom">2.89×10-2</td></tr><tr><td align="left" valign="bottom">HHV-6B</td><td align="left" valign="bottom">0.93 (0.70–1.23)</td><td align="left" valign="bottom">0.59</td></tr><tr><td align="left" valign="bottom">HHV-7</td><td align="left" valign="bottom">0.79 (0.60–1.03)</td><td align="left" valign="bottom">8.33×10-2</td></tr><tr><td align="left" valign="bottom">KSHV</td><td align="left" valign="bottom">0.89 (0.44–1.80)</td><td align="left" valign="bottom">0.74</td></tr><tr><td align="left" valign="bottom">VZV</td><td align="left" valign="bottom">1.70 (1.02–2.82)</td><td align="left" valign="bottom">4.25×10-2</td></tr><tr><td align="left" valign="bottom"><bold>Parvovirus</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">PVB-19</td><td align="left" valign="bottom">0.90 (0.68–1.21)</td><td align="left" valign="bottom">0.49</td></tr><tr><td align="left" valign="bottom"><bold>Bacteria</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom">.</td></tr><tr><td align="left" valign="bottom"><italic>C. trachomatis</italic></td><td align="left" valign="bottom">1.45 (1.11–1.91)</td><td align="left" valign="bottom">7.22×10-3</td></tr><tr><td align="left" valign="bottom"><italic>F. nucleatum</italic></td><td align="left" valign="bottom">1.66 (1.20–2.29)</td><td align="left" valign="bottom">2.32×10-3</td></tr><tr><td align="left" valign="bottom"><italic>H. pylori</italic></td><td align="left" valign="bottom">0.95 (0.67–1.34)</td><td align="left" valign="bottom">0.78</td></tr><tr><td align="left" valign="bottom"><italic>S. gallolyticus</italic></td><td align="left" valign="bottom">0.62 (0.26–1.51)</td><td align="left" valign="bottom">0.29</td></tr><tr><td align="left" valign="bottom"><bold>Parasite</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>T. gondii</italic></td><td align="left" valign="bottom">1.17 (0.90–1.54)</td><td align="left" valign="bottom">0.25</td></tr><tr><td align="left" valign="bottom"><bold>Pathogen burden</bold></td><td align="left" valign="bottom">1.11 (1.03–1.18)</td><td align="left" valign="bottom">3.25×10<sup>−3</sup></td></tr></tbody></table><table-wrap-foot><fn id="app1table2fn1"><label>*</label><p>HR = hazard ratio, CI = confidence interval.</p></fn><fn id="app1table2fn2"><label>†</label><p>log10-transformed.</p></fn></table-wrap-foot></table-wrap></sec></app><app id="appendix-2"><title>Appendix 2</title><sec sec-type="appendix" id="s9"><title>Additional figures</title><fig id="app2fig1" position="float"><label>Appendix 2—figure 1.</label><caption><title>Pairwise correlations between quantitative characteristics significantly associated with coronary heart disease (CHD) risk in the univariable Cox proportional hazard models.</title><p>Pearson’s correlation values are displayed, along with linear fits between variables.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79742-app2-fig1-v1.tif"/></fig><fig id="app2fig2" position="float"><label>Appendix 2—figure 2.</label><caption><title>Strength of association for each pair of categorical variables significantly associated with coronary heart disease (CHD) risk in univariable Cox proportional hazard models.</title><p>Cramer’s V values are displayed.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79742-app2-fig2-v1.tif"/></fig><fig id="app2fig3" position="float"><label>Appendix 2—figure 3.</label><caption><title>Graphical test of proportional hazards assumption (Schoenfeld test).</title><p>The graphs show the scaled Schoenfeld residuals over time. The p-values (<bold>p</bold>) of the variables and the model as a whole were shown in the plot. A significant p-value (&lt; 0.05) indicates that the variable violates the proportional hazard assumption. The solid line represents the smoothing fitted spline, and the dashed lines the confidence bands at two standard errors. Global Schoenfeld test p=0.58.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79742-app2-fig3-v1.tif"/></fig><fig id="app2fig4" position="float"><label>Appendix 2—figure 4.</label><caption><title>Distribution of individuals according to their exposure to infectious agents (pathogen burden).</title><p>Bar plot showing the number of participants for each cumulative number of positive serological results, reflecting simultaneous ongoing chronic/latent infections. Sample sizes for each group are shown above the box.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79742-app2-fig4-v1.tif"/></fig></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79742.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nsengimana</surname><given-names>Jérémie</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kj2bm70</institution-id><institution>Newcastle University</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.04.13.22273812" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.13.22273812"/></front-stub><body><p>This study is an important contribution to the understanding of cardiovascular disease aetiology based on solid design and methodology. It is a useful independent replication of the effects of traditional risk factors in a large prospective cohort and a valuable investigation of the role of past infection with a commensal bacterium F. nucleatum which warrants validation.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79742.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nsengimana</surname><given-names>Jérémie</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kj2bm70</institution-id><institution>Newcastle University</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Bouatia-Naji</surname><given-names>Nabila</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vjkv261</institution-id><institution>INSERM</institution></institution-wrap><country>France</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.13.22273812">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.04.13.22273812v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Associations of genetic and infectious risk factors with coronary heart disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by David James as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Nabila Bouatia-Naji (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. You should limit your description of the traditional risk factors and genetic risk scores as this is not the main focus of their analyses. An introduction to the expected mechanisms linking infection and inflammation and link with atherosclerosis is missing. It would also be good to have a comment on any pre-existing GWAS on seropositivity for F. nucleatum.</p><p>2. A brief discussion should be included on the implications of conducting multiple tests</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. Multiple risk factors were investigated in univariable analysis before their combination into multivariable models. The authors should add to the discussion multiple testing implications</p><p>2. Why was no statistical interaction considered?</p><p>3. Was there any correlation between Fusobacterium nucleatum with hs-CRP or TNF-a? It would be interesting to know if inflammation is predictive of CHD in multivariable models excluding F. nucleatum</p><p>4. Adjusting principal components should be described in Methods not in Results</p><p>5. Table 1 title shows n=3462 subjects instead of 3459</p><p>6. Table 1 shows Statin=No for 8.6% of the cohort but Figure 2 shows that is probably Statin=yes instead</p><p>7. On figure 2 the numbers for all factors do not add up to those in table 1 - please indicate if it is due to missingness in multivariable analysis</p><p>8. Supplementary figure 1: scatter plot involving income looks odd. Best fit line does not make sense with income categorised</p><p>9. Supplementary figure 2: correlation coefficient between binary variables does not make much sense either. Pairwise association as chi2 test or Cramer V is more appropriate</p><p>10. Use correct notation for pvalues (e.g. 2.58e-01=0.26; 2.58e-08=3x10-8)</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The manuscript is very well organized and has several strengths. The methodology is very solid.</p><p>1. The authors should limit their description of the traditional risk factors and genetic risk scores as this is not the main focus of their analyses. Overall, the investigation of the genetic score seems artificial to me in the context of the scientific questions of the study.</p><p>2. Although I do think the results are sound, the study is overall descriptive and do not provide any support toward a mechanism until we get into the discussion.</p><p>3. I understand the article is built as an unbiased approach to test the broad hypothesis of how response to infection may predict the risk for CHD, but some introduction to the expected mechanisms linking infection to low grade inflammation in link to atherosclerosis is missing in the current version of the article, and I would have found it helpful to follow the reasoning of the authors.</p><p>4. Also, could the authors comment on potentially pre-exisitng GWAS about infection (or seropositivity for <italic>F. nucleatum</italic>)? Their current numbers do not allow this investigation of course.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79742.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. Multiple risk factors were investigated in univariable analysis before their combination into multivariable models. The authors should add to the discussion multiple testing implications</p></disp-quote><p>Although multiple univariable testing is a useful statistical tool, it can lead to an increase in the Type I error rate, which means that false positives become more likely when a large number of hypotheses are tested simultaneously. One sentence addressing the implication of multiple testing has been added to the discussion.</p><disp-quote content-type="editor-comment"><p>2. Why was no statistical interaction considered?</p></disp-quote><p>No statistical interactions were considered in our analysis because adding an interaction term to the survival analysis model increases the complexity of the model and limits its interpretability. In addition, adding an interaction term to the model may increase the risk of overfitting, which may lead to incorrect conclusions. Finally, the multivariate survival analysis used in this study still allows us to examine interdependency between multiple variables.</p><disp-quote content-type="editor-comment"><p>3. Was there any correlation between Fusobacterium nucleatum with hs-CRP or TNF-a? It would be interesting to know if inflammation is predictive of CHD in multivariable models excluding F. nucleatum</p></disp-quote><p>We performed a t-test to compare levels of biomarkers of inflammation between seronegative and seropositive individuals. The results showed no statistical difference in hs-CRP or TNF-a levels according to <italic>F. nucleatum</italic> serostatus.</p><p>Previous studies have shown that elevated levels of inflammatory markers in the blood, such as hs-CRP, are indeed associated with an increased risk of developing CHD (1, 2). In our study, we also observed significant association between CRP and the occurrence of CHD, independent of <italic>F. nucleatum</italic> serological status. However, this signal was not significant anymore with the addition of other variables such as SCORE2 and statin use.</p><disp-quote content-type="editor-comment"><p>4. Adjusting principal components should be described in Methods not in Results</p></disp-quote><p>We thank you for this suggestion. This part has been moved to Methods.</p><disp-quote content-type="editor-comment"><p>5. Table 1 title shows n=3462 subjects instead of 3459</p></disp-quote><p>This has been corrected, thank you for noticing.</p><disp-quote content-type="editor-comment"><p>6. Table 1 shows Statin=No for 8.6% of the cohort but Figure 2 shows that is probably Statin=yes instead</p></disp-quote><p>This has been corrected, thank you for noticing.</p><disp-quote content-type="editor-comment"><p>7. On figure 2 the numbers for all factors do not add up to those in table 1 - please indicate if it is due to missingness in multivariable analysis</p></disp-quote><p>Thank you for noticing, indeed, the multivariate Cox proportional hazards model was run on data from 2’323 individuals with non-missing data. This has been clarified in the manuscript (see Methods &gt; Multivariable Model).</p><disp-quote content-type="editor-comment"><p>8. Supplementary figure 1: scatter plot involving income looks odd. Best fit line does not make sense with income categorised</p></disp-quote><p>We agree with the reviewer, so we have moved income with the other categorical variables into Appendix 2 - Figure 2.</p><disp-quote content-type="editor-comment"><p>9. Supplementary figure 2: correlation coefficient between binary variables does not make much sense either. Pairwise association as chi2 test or Cramer V is more appropriate</p></disp-quote><p>We thank you for this suggestion. We now use Cramer's V coefficients, which are more appropriate than the correlation coefficient in this context, and adapted the Methods section accordingly.</p><disp-quote content-type="editor-comment"><p>10. Use correct notation for pvalues (e.g. 2.58e-01=0.26; 2.58e-08=3x10-8)</p></disp-quote><p>This has been corrected, thank you.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The manuscript is very well organized and has several strengths. The methodology is very solid.</p><p>1. The authors should limit their description of the traditional risk factors and genetic risk scores as this is not the main focus of their analyses. Overall, the investigation of the genetic score seems artificial to me in the context of the scientific questions of the study.</p></disp-quote><p>The study aims to delineate the effects of genetic variation, infections, and low-grade inflammation on CHD risk. In particular, the genetic score is a measure of genetic variation that can be used to assess an individual's risk of CHD. It was therefore essential for us to describe it, alongside the traditional risks, and to use it throughout the study to control for other factors that might influence the outcome and to assess their relative importance compared with the other factors studied.</p><disp-quote content-type="editor-comment"><p>2. Although I do think the results are sound, the study is overall descriptive and do not provide any support toward a mechanism until we get into the discussion.</p></disp-quote><p>We agree that our study is essentially descriptive, due to the very nature of the analyses. We used statistical approaches to identify associations between several exposures and coronary artery disease. Additional, functional work is required to demonstrate potential causality, which prevents us from providing mechanistic insights in the Results section. Therefore, we think that it is appropriate to restrict speculations about potential mechanisms to the Discussion.</p><disp-quote content-type="editor-comment"><p>3. I understand the article is built as an unbiased approach to test the broad hypothesis of how response to infection may predict the risk for CHD, but some introduction to the expected mechanisms linking infection to low grade inflammation in link to atherosclerosis is missing in the current version of the article, and I would have found it helpful to follow the reasoning of the authors.</p></disp-quote><p>We thank you for highlighting the importance of introducing the expected mechanisms linking infection to low-grade inflammation, in link to atherosclerosis.</p><p>The exact mechanisms linking infection to low-grade inflammation and atherosclerosis are still being studied, though some potential pathways have been proposed. One proposed mechanism involves the production of pro-inflammatory molecules in response to infection (3). These molecules, such as cytokines, can increase the activity of cells involved in atherosclerosis, such as macrophages and smooth muscle cells, leading to the formation of plaques and other changes in the walls of arteries (3). Another mechanism is related to the inflammation at the site of vessel wall. Specifically, it is characterized by the presence of the infectious agents within the atherosclerotic plaques but not within normal blood vessels. The infectious consequences on the atherosclerotic plaque can be accelerated progression or a final complication like thrombosis and plaque rupture (4).</p><p>A paragraph explaining these mechanisms has been added to the Introduction section.</p><disp-quote content-type="editor-comment"><p>4. Also, could the authors comment on potentially pre-exisitng GWAS about infection (or seropositivity for <italic>F. nucleatum</italic>)? Their current numbers do not allow this investigation of course.</p></disp-quote><p>To our knowledge, no GWAS on <italic>Fusobacterium nucleatum</italic> has been published to date, neither on humoral immune response (i.e., IgG levels) nor on susceptibility to infection / colonization (i.e., serostatus). This information has been added to the Discussion.</p><p>References</p><p>(1) Casas, J. P., Shah, T., Hingorani, A. D., Danesh, J., &amp; Pepys, M. B. (2008). C‐reactive protein and coronary heart disease: a critical review. <italic>Journal of internal medicine</italic>, <italic>264</italic>(4), 295-314.</p><p>(2) C Reactive Protein Coronary Heart Disease Genetics Collaboration. (2011). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. <italic>Bmj</italic>, <italic>342</italic>.</p><p>(3) Campbell, L. A., &amp; Rosenfeld, M. E. (2015). Infection and atherosclerosis development. <italic>Archives of medical research</italic>, <italic>46</italic>(5), 339-350.</p><p>(4) Pedicino, D., Giglio, A. F., Galiffa, V. A., Cialdella, P., Trotta, F., Graziani, F., &amp; Liuzzo, G. (2013). Infections, immunity and atherosclerosis: pathogenic mechanisms and unsolved questions. <italic>International journal of cardiology</italic>, <italic>166</italic>(3), 572-583.</p></body></sub-article></article>